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ABSTRACT
Helicobacter pylori colonizes the human stomach and causes
gastroduodenal complications ranging from ulcer disease to cancer. A
major virulence determinant of this pathogen is the cag Pathogenicity
Island (cag PAI), and isolates possessing this element are more
frequently associated with severe disease outcomes. In many
bacterial species, prophage are also frequently associated with
bacterial virulence. The work presented in this thesis aims to
characterize the completeness, location, and effects of prophage
DNA across different clinical isolates of H. pylori. In addition,
identification of potential antivirulence loci and the potential for strains
to produce viral particles following induction are investigated.
PCR data indicate a significant correlation between the
absence of prophage sequence and the presence of the cag PAI in
our collection of clinical isolates. Additionally, among the cag PAI(-)
strains possessing prophage elements, there appears to be
preferential insertion of these elements into the H. pylori
chromosomal gene HP0453. In sequenced cag PAI(+) strains that
harbor prophage, three different intergenic chromosomal insertion
sites were identified. The most prevalent insertion site, located
between chromosomal genes Ipxd and metK, was analyzed using
NCBI database tools. This analysis revealed potential bacteriophage
att recombination site sequences and novel insertion site
characteristics.
Supporting recently published studies (mBio, 2011 Nov 15;2[6]
and J Virol., 2012 Jun 13 [Epub ahead of print]), TEM and
epifluorescence microscopy have indicated the presence of viral
sized particles from clinical isolates possessing complete prophage
sequence that were induced with UV irradiation. Despite the
successful generation of a vector for use in the creation of a
prophage knockout mutant, attempts at deletion of this locus have
been unsuccessful. Continued investigation will enable a better
understanding of important virulence mechanisms and the role
prophage play in this clinically-relevant species.
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Helicobacter p y lo r i: A B rief Overview
Discovered in 1982 by Barry Marshall and Robin Warren, H. pylori is a widespread,
gram-negative human pathogen infecting over half of the world's population. Infection rates
are generally higher in developing countries, and transmission is thought to occur via a fecaloral route (1-3). Specifically, colonization of new human hosts is posited to most often be a
result of transmission from parent to child in the early years of life. Genetically, H. pylori is
highly heterogeneous and is divided into sub-species groupings known colloquially as
“strains” (4). The bacterium is microaerophilic, approximately 3 pM in length, spiral-shaped,
and possesses between four to six flagella (5). It is unique in both its ability to colonize the
human gastric mucosa and its characterization as the only known bacterial carcinogen.
Though 80% of infected individuals are asymptomatic, infection with H. pylori is associated
with the development of gastritis, as well as gastric and duodenal ulcers and cancers. In
addition, several studies have linked infection to the development of autoimmune diseases
such as Lupus and Sjogren's syndrome (6).
Infection is commonly diagnosed via urea breath or stool antigen tests, while the
efficacy of real-time PCR for diagnosis is currently being tested (7). In locations with
adequate access to medical services, H. pylori infection can generally be treated with
antibiotic therapy. Specifically, first-line therapy regimens include the seven-day use of a
proton pump inhibitor, combined with amoxicillin, clarithromycin and/or metronidazole.
Unfortunately, a rise in antibiotic resistance has decreased the efficacy of triple-antibiotic
therapy in recent years. Clarithromycin, prescribed heavily in many countries for the
treatment of bacterial respiratory infections, has caused localized increases in resistance. In
these localities, quadruple-drug treatment as first line therapy (metronidazole, omeprazole,
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bismuth subcitrate, and tetracycline) outperforms standard triple-therapy. Given the rise in
resistance and rates of reinfection, alternatives to standard antibiotic treatments are being
investigated (8).
Disease outcomes vary from patient to patient; diet, infection duration, age at
infection, and other environmental factors have been implicated. Recently, human host
genetic variation has also been suggested as a cause of at least a portion of this variation,
with polymorphisms in certain cytokine genes altering gastric cancer risk in infected patients.
Regarding H. pylori virulence, more severe disease outcomes are linked to infection by
strains possessing a contiguous suite of genes known collectively as the cag Pathogenicity
Island {cag PAI). In addition to the cag island, H. pylori possesses several notable virulence
factors that affect disease severity, including proteins responsible for vacuolation and
induction of inflammation (9,10).

Major H. pylori Virulence Factors: VacA, DupA, OipA, HtrA, CagA
VacA
VacA is both a secreted and membrane-bound protein encoded for by the vacA gene in
H. pylori. Alleles of vacA (vacuolating cytotoxin) vary by geographic region, with certain
types being associated with increased risk of developing gastric cancer and peptic ulcer
disease. To date, several roles have been described for the VacA protein. The best described is
its ability to cause vacuole formation in infected host cells. Specifically, secreted VacA can
oligomerize and bind to host cell membranes. Endocytosis of the VacA complexes ensues,
and within these endosomes the oligomerized VacA is localized to the endosomal
membranes, forming anion-selective channels in the lipid bilayers. Eventually, the movement
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of ions through these channels and resultant pH gradient changes causes cell vacuolation as
the endosomes swell (11).
In addition to cell vacuolation, VacA has been shown to localize to the mitochondrial
membrane of host epithelial cells, causing the release of cytochrome C, disrupting
transmembrane potential, and reducing cellular ATP production. It is thought that VacA forms
membrane channels in the mitochondria similar to those formed in endosomes. As a result of
the described mitochondrial disruptions, pro-apoptotic pathways are activated and cell death
can occur. VacA has also been shown to reduce T-cell expression of Interleukin-2 while
increasing production of interleukin-6 and TNF-alpha by mast cells (12). Its complex and
multi-functional nature make VacA a continued point of study in H. pylori pathogenesis.
DupA
dupA (duodenal ulcer promoting gene A) was first identified as encoding a virulence
factor in 2005 by Lu et al. Its mechanism of action is still unclear, but in vivo studies
involving dupA mutants point to its ability to increase production of various proinflammatory interleukins in CD 14+ cells. The gene encoding dupA shows homology to an
ATPase component of another Type-IV secretion system in H. pylori, virB4 of the cag PAI.
Infection with strains of H. pylori with functional dupA genes are more frequently associated
with the development of duodenal ulcers and less frequently associated with gastric cancers
(13).
OipA
Gene oipA codes for the H. pylori outer membrane protein OipA, responsible for
proper adhesion of the bacteria to host gastric epithelial cells. Much like the previously
mentioned virulence factors, it has been shown to induce production of pro-inflammatory
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cytokines. Additionally, studies have shown significant overlap in host epithelial cell
pathway activation for OipA and CagA. The transcription of oipA correlates with the
presence of the cag PAI and interestingly, OipA is as an independent factor in the
development of gastric cancer (14,15).
HtrA
Secreted by H. pylori into the extracellular space, HtrA is a member of the protease
and chaperone protein families . Recent studies demonstrated that HtrA has proteolytic
activity that results in the cleavage and release of host cell, membrane-bound E-cadherin.
Specifically, E-cadherin cleavage and loss results in decreased cellular adhesion and impaired
tumor suppression. These events have been identified as a marker for gastric cancer
development (16).
CagA
Finally, CagA, one of the most-studied H. pylori virulence factors, is encoded by a
gene on the cag Pathogenicity Island. It is a potent bacterial oncoprotein and can be divided
into two sub-types (East Asian and Western) based on the 3’ coding sequence of its gene,
cag A. The CagA protein is translocated to host cells via a Type-IV secretion system whose
proteins are also encoded for by genes on the cag PAI. Following translocation, CagA is
phosphorylated by gastric epithelial cell tyrosine kinases. Both phosphorylated and
unphosphorylated CagA then interfere with multiple intercellular signaling pathways,
including those involved in apoptosis and the inflammatory response (14,17). The following
section details the molecular mechanisms of Type-IV secretion systems (T4SSs) and
translocated CagA.
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Type-IV Secretion Systems and the cag Pathogenicity Island
Pathogenic bacteria employ a variety of strategies during infection to affect and
debilitate host cells. The production and release of toxins and signaling molecules is one such
strategy. Such effector proteins (and in some cases DNA) can be directly released from the
bacterium into intercellular space. In many cases, specific systems exist to direct the
transport of these molecules from the bacterium directly into a target cell. Secretion systems
are generally well conserved and can be broadly classified into six sub-groupings based upon
protein subunit composition and mechanism of action. They are found in both gram-positive
and gram-negative bacteria. Additionally, due to their role in bacterial pathogenesis, they are
of great interest from a clinical perspective. It is important to note that bacterial secretion
systems are not limited to roles in pathogenesis, but are integral parts of conjugation and
horizontal transfer of genetic material as well (18,19).
The generally accepted model for T4SSs is derived from the structures found in the
bacterium Agrobacterium tumafaciens. Further delineations can be made between specific
subtypes of Type IV systems based on either function or relative similarity to the
Agrobacterium and Legionella T4SSs (20, 21). There are three Type-IV sub-families defined
by function. The first category includes T4SSs involved in the uptake and release of DNA.
Modulation of genetic exchange via this system is completely independent of direct contact
with a target cell and is not directly involved in pathogenesis. The second function-defined
category encompasses bacterial conjugation. This is similar to the first category with the
exception of contact-dependency and the specific proteins associated with this type of
contact. The third and final subcategory includes T4SSs responsible for movement of effector
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proteins and DNA into a target cell. This variety of T4SS is most commonly associated with
pathogenesis.
The second classification system, based on a T4SS's relationship to either the
Agmbacterium_model or Legionella bacterium model, proceeds as follows. The first
subcategory is designated IV-A and signifies a near-homologous relationship to the
Agrobacterium system. The second subcategory, IV-B, signifies a near-homologous
relationship the T4SS of Legionella pneumophila. The third subcategory is a catchall for
T4SSs that bear little resemblance to either the IV-A or IV-B systems.
A. tumafaciens, a gram-negative soil bacterium, is the “archetypal” system . It is
responsible for crown gall disease, which results in the production of tumors in infected
plants. These tumors produce opines, a type of amino acid that the bacterium can then
metabolize. Tumors appear specifically because of the integration of a bacterial plasmid
secreted by A. tumafaciens’ T4SS that encodes for tumor-induction genes as well as enzymes
involved in the generation of opines.
Approximately fifteen genes and their subsequent protein products are involved in the
assembly and function of this IV-AT4SS. These proteins can be divided into three major
groupings based on their functions. The first two groups, coupling and transenvelope
proteins, work together to recruit cargo DNA or proteins to the T4SS site. Coupling proteins
are proposed to be responsible for the majority of cargo recruitment within the bacterium,
while transevelope proteins compose the avenue by which the cargo travels for cell exit. The
third group of proteins make up the pilus, a filamentous helix with two associate proteins
(VirB2, VirB5, and VirB7). The pilus is responsible for delivery of the cargo across the
intercellular space to the target cell.
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No direct imaging has been conducted to elucidate Agrobacterium tumafaciens’ T4SS
structure. Based on the results of a multitude of dihybrid and biochemical assays conducted
in yeast however, two main models for system assembly have been proposed. The first or
“Piston” model has coupling and transenvelope proteins arranged symmetrically, enclosing
the pilus inside the outer cell membrane. Cargo is recruited by coupling proteins to the pilus,
which then acts like a piston, pushing the cargo either into the intracellular space or directly
into a target cell. The second model is passive relative to the “piston” arrangement. It
involves a similar symmetrical arrangement of transenvelope proteins with a centrally
located pilus. In this model, however, the pilus forms a direct channel to either the
intracellular space/target cell; a conformational change on the scale of the “piston” model
does not take place (22).
Some strains of Helicobacter pylori also harbor a T4SS, encoded by the suite of genes
comprising the cag Pathogenicity Island. The cag PAI is approximately 37,000 base pairs in
length and codes for approximately 29 genes. The majority of these genes are involved in the
assembly of a unique T4SS that shares a high degree of general homology with the
traditional IV-A T4SS. In addition to the system itself, the cag PAI genes also encode for the
effector gene product, CagA: an effector that acts as a bacterial oncoprotein.
During host infection, cag PAI (+) strains o f H. pylori express T4SS proteins that
assemble in and span both the inner and outer bacterial membranes. Recruitment of cargo by
coupling proteins directs CagA and CagL proteins, as well peptidoglycans, to the secretion
apparatus. Extension of a needle-like pilus completes the pathway between the bacterial and
host cells, allowing for the transport of the effector protein cargo.
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Recent evolutionary studies have identified interesting trends specific to H. pylori’s
unique T4SS. Based on sequence analysis of cag PAI genes in myriad strains representing
different geographical sub groupings, researchers calculated Ka/Ks ratios for use as
indicators of selective pressure. Specifically, the Ka/Ks ratio is the number of nonsynonymous substitutions per non-synonymous site to the number of substitutions per
synonymous site. Based on this method, genes with high Ka/Ks ratios are under greater
positive selection. The study concluded that T4SS structural proteins that spanned the region
between the inner and outer cell membranes faced relatively low-to-no selective pressure.
Conversely, proteins positioned past the outer cell membrane in intercellular space,
(specifically the B2, B5, and BIO subunits that form the pilus) were under a high degree of
selective pressure. Additionally, the effector protein (CagA) was under the highest level of
positive selective pressure (23).
Recent research has highlighted the unique nature of CagA as a multi-faceted effector
protein. Approximately twenty different host cell binding protein partners have been
identified. Following translocation into the host cell via the T4SS, CagA is phosphorylated
by host cell tyrosine kinases. Following phosphorylation, CagA is able to modify multiple
intracellular signaling cascades. These interactions result in modification of the host cell
phenotype (transformation to elongated form) and activation of Ras-MAPK (the latter effect
increases carcinogenesis likelihood), among others. In addition to its effects post
phosphorylation, CagA exerts influence in the host cell in an unphosphorylated form via
interaction with host proteins. Examples include the loss of tight junctions via ZO l-CagA
interactions, induction of inflammatory and mitogenic responses via Erk-CagA & Grb2CagA interactions, and an overall loss of cell polarity via Pari-CagA interactions (24).

Interestingly, a recent study demonstrated that translocation o f CagA via the T4SS
can be greatly attenuated by reducing the cholesterol content o f host cell membranes. The
authors hypothesize that “cholesterol might act as a ubiquitous eukaryotic ‘raft-associated
receptor/co-receptor’ that facilitates H. pylori recognition of the host cell surface and
influences (T4SS) integration into the membrane and subsequent translocation o f CagA
across the membrane.'” From a therapeutic standpoint, this finding has important implications
for a range of gastrointestinal pathogens due to their similar utilization of cholesterol-rich
“lipid rafts” in host cell membranes (25).

Antivirulence Loci
While much attention is given to the characterization o f virulence factors,
identification of potential “antivirulence” loci is often overlooked. Bacteria have several
mechanisms by which to acquire new genetic material, including transduction o f DNA via
bacteriophage and the uptake o f plasmids. Via such routes, the acquisition and subsequent
expression of virulence factors alters a bacterium's fitness in its niche and introduces new
selective pressures. Any genes that negatively affect the bacterium's fitness post-acquisition
and expression of its new genes are termed “antivirulent.” As selection acts on these genes,
mutations in or deletions of the genes may occur. By comparing more virulent strains o f a
bacterium against its less virulent counterparts, it is possible to identify such antivirulence
genes.
Specifically, Maurelli et al. describe two requirements for the designation o f a gene as
antivirulent. First, the “gene must be present and expressed in closely related or ancestral
species occupying the nonvirulent ancestral niche but absent (or mutated) from pathogenic
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clones that colonize host tissues.” Second, “expression of the antivirulence gene by the
pathogen in host tissues must attenuate virulence and/or inhibit fitness”(26). To date, no
anti virulence loci have been proposed or identified in Helicobacter pylori. Identification of
such loci would be beneficial in reconstructing H. pylori's evolutionary history and
improving the characterization of its virulence mechanisms.

Bacteriophage and Their Effects on Host Cells
First described in the early 20th century, bacteriophage are a large class of viruses that
infect bacteria (including many clinically relevant species). Phages generally have a narrow
host range and belong to one of the 13 recognized bacteriophage families classified by the
ICTV (International Committee on Taxonomy of Viruses)(27). Groups of bacteriophage that
are able to infect the same host have often shown sequence homology amongst themselves of
over 90%. Importantly, within a single bacteriophage species, even small variations in
genomic sequence can result in phenotypic changes that alter the phage's infectivity range
and/or efficacy at evading host immune defenses (28).
Bacteriophage have two strategies for genome replication and virion production: lysis
or lysogeny. Some phage are purely lytic, infecting bacterial cells and commandeering host
molecular machinery to produce copies of themselves. Virions are then released either
through lysis of the infected cell or secretion through specialized membrane-spanning
channels. Lysogeny involves infection of host cells and the directed integration of the
bacteriophage genome into the host chromosome. Once integrated, the phage is now termed a
“prophage.” Low-level transcription and translation of phage-encoded repressor genes (and
occasionally regulation by host cell proteins) maintains this lysogenic state. Even during
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lysogeny, prophage can exert effects on their host by expressing encoded toxin genes,
regulating host gene expression, altering cell mobility, and even changing group/swarming
behavior. Depending on the species of phage and infected host, induction (excision of the
phage genome and entry into the lytic cycle) can be triggered by a range of stimuli, including
oxidative stress and DNA damage (29).
Some bacterial cells are capable of defending themselves from phage infection or
prophage induction however, via the use of recently discovered CRISPR (Clustered
Regularly Interspaced Short Palindromic Repeats) systems. To date, eight different CRISPR
system variants have been described. These systems provide bacteria with a rudimentary
adaptive immune system to protect against foreign DNA from both plasmids and
bacteriophage. CRISPR systems, at the chromosomal level, possess an “array”. An array is
composed of multiple 24-48 base pair repeats separated by “spacers” (short DNA sequences
homologous to plasmid, phage, or even host DNA sequences). These spacer-repeat regions
are then often flanked by several CRISPR-associated (cas) genes. During infection by a virus
or after acquisition of a plasmid, cas-encoded proteins process invading DNA into short
segments and incorporate some of them into the repeat region of the CRISPR array as
spacers. Transcription of this region and processing of the resulting RNA results in the
production of small RNAs that direct other c^-encoded proteins to interfere with invading
genetic material both at the RNA and DNA levels (30). Additionally, work by Edgar et al.
shows that, in addition to preventing lysogeny by phage, induced CRISPR systems can
successfully target integrated prophage and even “cure” a lysogenic bacterium by destroying
the prophage during induction (31).
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Prophage Chromosomal Fate and Selective Pressures
While prophage have been shown to integrate primarily into host tRNA genes, some
have also demonstrated insertion into host intergenic regions and open reading frames.
Because prophage recombination sites often match chromosomal sequences closely enough,
protein products are not affected. It is possible, however, that integration results in a modified
or non-functional protein product. Prophage achieve integration into a host’s genome using
an attP recombination site. Occasionally, the attP site is located in the middle of a prophage’s
integrase gene, causing disruption of the gene upon insertion (and, as some propose,
stabilization of the lysogen) (32).
Though no mechanism has been elucidated, the majority of prophage preferentially
orient their genes in the same direction as surrounding host chromosomal genes. Among
closely related strains of the same bacterial species that have been lysogenized by a
prophage, the majority of genetic alignment disparities between them result from sequence
variation in the region encompassing the prophage’s insertion location. A likely contributor to
these disparities is the mobile nature of prophage genetic elements. Integrated phage genes
are often sites of recombination, and these recombination events can result in shuffling of
chromosomal DNA, causing “inversion” events involving portions of the genome flanking
prophage elements (33).
Upon successful integration into a host's genome, selective pressures acting on the
host now also affect the prophage. Expression of certain prophage genes can alter the
infected bacterium morphologically, physiologically, or metabolically, allowing it to expand
into new niches. Maurelli et al. term the host's adaption to these newly available niches as
“pathoadaptive evolution” (26,34). As per the previous discussion of antivirulence loci, one
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could envision many scenarios in which selective pressures resulted in the inactivation (or
deletion) of various prophage genes that have become “antivirulent.”

Prophage Impact on Host Genes and Fitness
In addition to the well-studied ability of some phages to carry toxin genes that are
subsequently expressed after chromosomal integration, prophage can exert a multitude of
other effects on their hosts. Previously studies have shown that prophage have effects on
bacterial colonization and adhesion, invasion, resistance to serum and phagocytes, and
transmission. More recently, several studies have identified novel alterations of host gene
expression by prophage gene products.
Su et al., using microarray and qRT-PCR data collected from Stx2 E. coli lysogens,
discovered that integrated prophage altered expression more than two-fold for 166 host
genes. Among the 104 up-regulated genes were those encoding flagellar proteins, enzymes
involved in metabolic processes, chemotaxis, acid-resistance, LPS-synthesis, and membrane
and electron transport. Among the 62 down-regulated genes were those encoding products
involved in fatty acid and lipid metabolism, protein transport, the TCA cycle, and oxidative
stress responses. Experiments were also conducted to investigate motility and acid resistance
based on the data from the microarray results. Results demonstrated that Stx2 lysogens had
both enhanced swimming motility and increased resistance to lower environmental pH
relative to controls (33).
In the gram-positive bacterium Clostridium difficile, lysogeny by phage c()CD 119
directly impacts host chromosomally-encoded toxin gene regulation in a non strain-specific
manner. Govind et al., using data from ELISA, RT-PCR, and gel-shift mobility assays
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discovered that lysogeny by 0CD119 of multiple C. difficile strains resulted in a 50%
decrease in toxin A production. Toxin A gene tcdA, along with tcdB/R/E/C (genes necessary
for toxin production and excretion), is located on a chromosomal pathogenicity island (PAI)
of approximately 19.6kb in length. The gene product of tcdR is an activator of tcdB and tcdA.
After further investigation, Govind et al. concluded that transcription of all five of the ted
genes on the PAI is downregulated due to the presence of c|)CDl 19-encoded RepR, a
repressor protein. RepR was found to bind directly to DNA in tcdA and tcdR promoter
regions on the PAI (35).
In addition to phage-encoded proteins binding directly to DNA, prophage products
have also been shown to directly alter transcription via interaction with host sigma (a)
factors, the promoter-specifying subunits of bacterial RNA polymerases. Dehbi et al.
investigated this phenomenon in Staphylococcus aureus strains containing G1 prophage.
Using a variety of protein affinity, in vitro transcription, and DNA-binding assays,
researchers demonstrated that G 10RF67 (a G1 phage-encoded polypeptide) inhibits S.
aureus growth. Specifically, it binds to the S. aureus-specific primary a factor SA (an integral
part of the RNA Polymerase holoenzyme) and prevents it from binding to target DNA. This
in turn inhibits the transcription of a multitude of host genes. The authors propose that the
inhibition of transcription of a factor SA-dependent genes allows the integrated phage to
enter later lytic phases by switching its transcriptional program to late life cycle genes (36).
Using the well-studied model systems of bacteriophage lambda (X) and E. coli, Chen
et al. compared gene transcription in E. coli X lysogens and controls. Microarray results
indicated a two-fold change in expression for eight host genes. Most notably, there was an
almost three-fold down regulation of the chromosomal gene pckA. pckA encodes
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Phosphoenolpyruvate carboxykinase, the enzyme mediating the rate-controlling step of
gluconeogenesis. Investigators then sought out any sequence homology between prophage X
and E. coli chromosomal regions. Several homologous regions were discovered, the strongest
match being for a region upstream of pckA and X Cl operator sites. Mobility shift assays and
RT-PCR confirmed that the X Cl repressor protein binds to the region upstream of pckA and
represses its transcription. Growth experiments indicated a 30% increase in generation time
when lysogens were grown with succinate relative to controls. Additionally, the pckA
regulatory region is highly conserved among the Enterobacteriacea, allowing the possibility
that X prophage-encoded Cl might exert similar effects in different species. Other
investigations of X -E. coli interactions by Osterhout et al. confirm the results of Chen et al.
with 10 chromosomal genes showing at least a two-fold change in expression (37).
Adding another layer of complexity to the study of prophage-host interactions,
Zegans et al. found interaction between lysogenic phage DMS3 and host CRISPR regions in
Pseudomonas aeruginosa strain PA 14. Importantly, these interactions effected P. aeruginosa
swarming motility and biofilm formation. Specifically, investigators first observed a decrease
in motility and biofilm formation in P. aeruginosa DMS3 lysogens. To determine if the
DMS3 prophage was mediating this decrease, a subset of lysogens were mutagenized and
populations were examined for cells demonstrating normal motility and biofilm formation.
One such mutant was isolated and characterized, revealing mutations in a region of the
genome containing cas genes flanked by two CRISPRs. Sequence analysis of this region
revealed spacers matching several bacteriophage species, including an identical match to a
portion of phage DMS3 gene 24. Recreating this finding via direct mutagenesis, a lysogenic
strain of P. aeruginosa was engineered with a deletion in the same mapped cas gene region.
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This strain also exhibited normal biofilm formation and swarming behavior. Finally,
investigators isolated non-mutagenized lysogenic strains exhibiting the same normal motility
and biofilm formation and found that they also possessed deletions in their cas gene region.
Based on these observations, the authors proposed that the biofilm and motility behaviors of
P. aeruginosa are mediated by its CRISPR systems. More specifically, they suggest that
since swarming and biofilm formation are behaviors that maximize proximity to and
interactions and with other cells, self down-regulation of such behaviors by lysogenic cells is
a potential bacterial strategy for minimizing the spread of bacteriophage to other uninfected
members of the population. Further investigations are underway to elucidate the actual
mechanisms (38).
The literature regarding the impact of fully intact prophage on their hosts is steadily
increasing, revealing a plethora of interactions. However, mutations and selective pressures
often result in bacterial strains that possess defective or cryptic prophage. Several
investigations have revealed that the genes of such incomplete prophage can still be
expressed absent of full induction. One well-documented phenomena is the secretion of
fragmented chromosomal DNA. Bacillus subtilis strain 168 possesses the defective prophage
PBSX. Investigation by Shingaki et al. revealed that under non-inducing conditions, B.
subtilis released chromosomal DNA fragments (without cell lysis) of approximately 13-kb
and 50-kb capable of mediating the transformation other cells. Disruption of PBSX genes,
individually and simultaneously, decreased or eliminated secretion and generation (via
chromosomal fragmentation) of these DNA fragments. Similar defective-prophage mediated
chromosome fragmentation and release has also been observed in Rhodobacter capsulatus,
Methanococcus voltae, Bartonella henselae, Bacillus natto, and Bartonella bacilliformis. In
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addition to the obvious consequences for horizontal gene transfer and the subsequent
potential advantages to maintaining defective prophage elements, extracellular DNA was also
reported to enhance biofilm structure generated by P. aergunisoa (39).

Prophage Maintenance & Induction
For intact prophage, the “decision” to maintain lysogeny or undergo induction and
entry into the lytic cycle is dynamic and complex. Using X as a model system, Osterhoust et
al. investigated E. coli lysogens and their response to prophage induction. Briefly, during
lysogeny, transcription and translation of X repressor protein Cl is primarily responsible for
keeping prophage genes transcriptionally silent. Upon UV damage, the SOS response in host
E. coli cells is activated, resulting in the modification of RecA and the subsequent cleavage
of Cl by active-form RecA. De-repression of X promoters results in progression towards the
lytic cycle via expression of lytic genes. RT-PCR and microarrays were used to examine
changes in prophage and host gene transcription during UV induction of E. coli lysogens.
The authors identified 728 E. coli genes altered upon induction of X but conclude that this
actually imposes a minimal load on the host and is largely independent until cell lysis.
Included in the altered expression of chromosomal genes were the notable activations of
general stress response pathways (Arc and Cpx) and their subsequent interactions with the
heat shock regulon (37).
Significantly, Cl is not the only player in the X lysogenic/lytic switch. Recently,
Glinkowska et a l described the role of OxyR, a transcription factor involved in the activation
of genes involved in the defensive antioxidant response in E. coli, in prophage X
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maintenance. Results from oxidative stress induction assays and gel mobility shift assays
conducted on oxyR mutants demonstrated an increase in phage induction relative to wild-type
lysogens caused by a lack of activated-OxyR binding to the X Pm promoter region. In turn,
this removed OxyR-mediated inhibition of Cl binding to X OR3. These results indicate that
prophage lysogeny is more effectively maintained during oxidative stress. This runs counter
to the general strategy of prophage to excise and replicate during times of cellular stress. The
authors address this apparently detrimental strategy by hypothesizing that oxidative stress,
unlike DNA damage (and subsequent induction via RecA cleavage of Cl), often involves
additional damage to molecules in the cell, like proteins. Entrance into the lytic cycle under
such conditions might be more detrimental to the phage than remaining lysogenic and
waiting for the host cell to recover. Additionally, they propose that if damage became too
severe, the SOS pathway would be activated to ensure induction as a backup strategy (40).
Interestingly, Selva et al. have described activation of a similar oxidative stress pathway in
Staphylococcus aureus by Streptococcus pneumoniae as a means to eliminate competitors.
Specifically, lysogenic S. aureus populations colonizing the nasopharynx of humans undergo
induction and cell lysis when they encounter increased levels of hydrogen peroxide. The
authors point out the involvement of S. pneumoniae, via its production of hydrogen peroxide,
in the “remote killing” by induction of nearby lysogenic S. aureus bacteria (41).
Monitoring of and responding to changing host conditions is of obvious importance to
a prophage. Additionally, the ability to “fine tune” switches and pathways involved in
responding to change host conditions to better “make” the “decision” to maintain lysogeny or
enter the lytic cycle would be evolutionarily advantageous. Refardt et al. describe
mechanisms for rapid selection of lysogenic/lytic “switches” with altered sensitivity and
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thresholds in a A, model system. E. coli lysogen cell cultures were propogated under various
DNA damage conditions and monitored for differences in induction sensitivity and
chromosomal gene sequence changes. One of their most important findings showed that the
strongest alterations in sensitivity to DNA damage occurred in populations that acquired
amino acid substitutions in the X Cl-coding region. The authors suggest that this location for
selective mutation makes sense because it would negatively effect Cl dimerization,
subsequently altering sensitivity to cleavage by RecA during an activated SOS-response
scenario. Additionally, more spontaneous induction of prophage was observed in sensitized
mutants, highlighting a tradeoff between increased sensitivity and destabilization of lysogeny
(42).
In addition to induction via the activation of traditional cellular stress response
pathways, Ghosh et al. describe prophage induction mediated by acyl-homoserine lactones
(AHL), molecules used in bacterial quorum sensing. Initially, results from experiments on
mixed populations of bacteria isolated from both soil and groundwater showed that AHLs
were able to increase induction and phage production relative to control populations. For a
more controlled investigation, the E. coli- X system was used in combination with P.
aeruginosa (produces two types of AHLs) and A. tumefaciens A 136 (a genetically engineered
mutant that produces light proportional to AHL concentration) with real-time AHL
monitoring via a biosensor. Results demonstrated that AHL produced by another species
could induce X prophage in E. coli lysogens (43). Further work is needed to elucidate the
specific SOS-independent pathway through which AHL causes induction.
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Prophage in H. pylori
Though first observed by Marshall et al. and Goodwin et al., Schmid et al. was the
first study to characterize bacteriophage in Helicobacter pylori in 1990. Their strain of
interest, SchReck (IMMi 290/89), was isolated from a gastric biopsy. After propagation of
the strain on blood agar plates, harvesting of the cells, and preparation for electron
microscopy by thin-sectioning, viral particles were observed. Specifically, particles possessed
hexagonal heads approximately 70 nm x 60 nm with tails measuring 120nm in length. This
phage was deemed HP1 (44). In 1993, the Schmid lab used Mitomycin C, UV irradiation,
and high temperatures to induce SchReck. HP1 viral particles were harvested from induced
samples and subsequently imaged and used to infect ten different clinical isolates of H.
pylori. Only two clinical isolates propagated a lytic infection. The remaining eight isolates
were shown to be immune to infection and negative for lysogeny by HP1 as evidenced by
their lack of viral particle production when treated with inducing agents (45).
Between 1993 and 2011, no publications were produced regarding bacteriophage in
H. pylori. Studies by Wan et al. and Lehours et al. were published in 2011 describing the
propagation of lytic infection and imaging of phage particles from induced H. pylori strains.
Additionally, in 2012 the Taiwanese group of Lou et al. published a comprehensive
bioinformatics analysis of sequenced H. pylori strains possessing all or part of an integrated
prophage, as well as images of viral particles from induced strains (46-48).
In 2004, Helicobacter acinonychis strain “Sheeba” was isolated via gastric biopsy
from several large zoo felines. It is believed that at some point in human history, H. pylori
made a species jum p to large felines during a predation event, resulting in the divergence to
the Helicobacter acinonychis species. Sheeba's genome has been completely sequenced. It
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harbors a prophage annotated as “Prophage II” (49). All sequencing and annotation of
prophage DNA in H. pylori genomes to-date have shown homology to the archetypal
Prophage II in Sheeba. As such, all new annotations of prophage DNA in H. pylori clinical
isolates use Sheeba's open reading frame annotations as a benchmark.
Previous work in our lab at the College of William and Mary identified a potential
correlation between the presence of the cag Pathogenicity Island in H. pylori clinical isolates
and the absence of prophage sequence, as determined by PCR screening for cagA and
bacteriophage integrase genes, respectively. The presence of the first eleven open reading
frames of prophage DNA has been confirmed, via genome walking, in the cag PAI negative
H. pylori strain J68. Additionally, the insertion location of prophage DNA in J68 was
determined to be in the middle of the coding region for J68's homologue of the 26695
chromosomal gene HP0453.
The aim of the work presented in this thesis is the characterization of the
completeness, location, and effects of prophage DNA across different clinical isolates. In
addition, identification of potential antivirulence loci and the potential for strains to produce
viral particles following induction are investigated.

Materials and Methods
PCR Screening of Clinical Isolates for Prophage ORFs and Insertion Locations
Genomic DNA was isolated from H. pylori clinical isolates obtained from Dr. Mark Forsyth's
collection. Strains were grown from freezer stock on B B L T SA II 5% Sheep's Blood agar plates
for three days and passed to a single new blood agar plate. After two to three days of growth,
cells were harvested and genomic DNA was extracted using phenokchloroform (Appendix A).
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Extracted DNA was quantified using Dr. Oliver Kerscher's Thermo Scientific Nanodrop 1000
Spectrophotometer. DNA was stored at -20° C.
Primers used in the screening were sourced from the work of previous lab members or
designed and ordered from Integrated DNA Technologies. Specifically, primers used to
interrogate the prophage's second, fourth (integrase gene) and sixth open reading frames, as well
as primers for H. pylori chromosomal genes HP0453 and p7, were obtained from Dr. Mark
Forsyth as products of his work and the work of Lauren O'Hagan. Primers used to interrogate
chromosomal genes IpxD and metK, as well as those for prophage open reading frames 11, 13,
17, and 23, were designed based on consensus DNA sequence between a minimum of three
sequenced H. pylori strains in the NCBI database.
PCR reactions were conducted as per the Forsyth's Lab standardized protocol (Appendix H)
using either a Labnet Multi Gene thermal cycler or Applied Biosystems 2720 thermal cycler.
Primer names, primer sequences, and primer melt temperatures, as well as complete thermal
cycler settings, are documented in Appendix B. Reaction volumes of 50 p.L were used for all
PCR experiments, as well as appropriate water and genomic DNA controls. Reaction products
were visualized via gel electrophoresis. Briefly, samples were mixed with an appropriate amount
of New England Biolabs 6X blue gel loading dye and loaded into 1% agarose gels containing
ethidium bromide. New England Biolabs lkb and/or lOObp DNA ladders were also utilized. Gels
were suspended in 0.5X TAE in Thermo Scientific Owl Easycast gel boxes. BioRad Power Pac
300 power supplies provided 100V of steady current for 30-45 minutes. Gels were imaged using
a Kodak Gel Logic 100 Imaging System combined with a Fisher Scientific UV Light box. Images
were visualized and processed with Kodak Medical Imaging software on an iMac.
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Analysis of Sequenced Strains via NCBI Database
To compare PCR screening data of clinical isolates from Dr. Forsyth's Lab to previously
sequenced NCBI database strains, as well as database strains against each other, several
bioinformatics tools were used. Prophage sequence data for strain J68, acquired via genome
walking by members of Dr. Forsyth's lab, was compared to database sequence information using
BLASTn, BLASTp, and BLASTx programs. These programs were also run to compare
sequenced Helicobacter database strains against each other with regard to prophage open reading
frames and prophage insertion locations. In addition, one accessory tool on the NCBI website
was heavily utilized. Highlighting individual sequences in a text-only format from GenBank
entries to be used for BLAST searches proved to be cumbersome. Use of the “Graphics”
hyperlink displayed under GenBank nucleotide listings provided a simple, graphics-heavy
interface via which one is able to search the genome of an organism for gene names or specific
sequences, all in the context of an annotated, interactive chromosome schematic.

Mitomycin C and UV Induction Protocols
To examine the ability of different strains to produce viral particles, inductions via
Mitomycin C antibiotic treatment and UV irradiation were separately attempted.
Mitomycin C inductions were executed using the “Protocol for Induction of One
Helicobacter pylori Strain” (Appendix J), designed collaboratively by Dr. Mark Forsyth and
Kevin Leslie. Briefly, strains were grown on three blood agar plates for one to two days at 37° C
in a 5% CCF environment. Cells were harvested and suspended in an SFBB-based broth
containing Vancomycin. These liquid cultures were incubated at 37° C in a rotating CCF incubator
for six hours. Mitomycin C was introduced to the liquid cultures after six hours of growth and
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cells were left to grow overnight. Following overnight incubation, cells were pelleted via
centrifugation and resuspended in fresh SFBB/Vancomycin broth. These resuspended cultures
were then returned to the 37° C rotating CO2 incubator for overnight incubation. Following
incubation, cultures were prepared for either epifluorescence or transmission electron
microscopy via methods detailed in the “Epifluorescence Microscopy” or “Transmission
Electron Microscopy” sections of this thesis.
UV Inductions were executed using the “//. pylori Single-Strain UV Induction Protocol”
(Appendix C) designed collaboratively by Dr. Mark Forsyth and Kevin Leslie. Briefly, strains
were grown for one day on three Blood Agar plates at 37° C in a 5% CCF atmosphere. After 24
hours of growth, plates were randomly labeled as “Control”, “X I”, and “X2”, designating
control and experimental samples. Using a Spectrolinker X L -1500 UV Crosslinker, 1.5mJ/cmf
and 2.5 mJ/cm2 of energy was delivered to the XI and X2 experimental plates, respectively.
Immediately following irradiation, cells were harvested and suspended in SFBB-based broth
with Vancomycin. These liquid cultures were incubated at 37° C and 5% CO2 in a rotating
incubator for 36 hours. Following incubation, cultures were prepared for either epifluorescence
or transmission electron microscopy via methods detailed in the “Epifluorescence Microscopy”
or “Transmission Electron Microscopy” sections of this thesis.

Epifluorescence Microscopy
To examine the presence of viral particles in induced samples, epifluorescence microscopy
was employed. Briefly, induced liquid cultures were centrifuged in 15 mL Falcon tubes for 10
minutes at 20° C and 4360RPM using a Hettich Universal 320 Zentrifugen and rotor #1615.
Following centrifugation, all supernatants were syringe-filtered using 18G 1 Vi needles and
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25mm Fisherbrand 22 (am Filters. Filtered supernatants were prepared for imaging according to
the protocol “Preparation of Fluorescently-Stained Virus Samples for Enumeration by
Epifluorescence Microscopy” (Appendix D) as recommended and provided by Dr. Kurt
Williamson. Briefly, filtered supernatants were loaded onto 25mm Whatman .02 pm filters
attached to a Millipore vacuum manifold. Samples were stained with 2.5X Invitrogen SYBR
Gold for 15 minutes. Anodiscs with stained samples were dried using the vacuum manifold and
mounted on glass slides with Antifade solution and coverslips. Slides were then stored at -20° C
degrees Celsius and protected from light exposure with aluminum foil.
Prepared slides were imaged using an Olympus B X 51 microscope with Olympus U-CMAD3
imaging adaptor, Hamamatsu C8484 Digital Camera, mercury bulb light source, and FITC lens
filter. MetaMorph Basic software for PC was used for image processing and visualization.

Transmission Electron Microscopy
To examine the morphology of potential viral particles from induced-culture filtered
supernatants, the “TEM Grid Preparation” (Appendix E) and “TEM Basic Operation Checklist”
(Appendix F) protocols, developed collaboratively by Dr. Kurt Williamson and Kevin Leslie,
were employed.
Briefly, filtered supernatants were pipetted onto Formvar copper grids (400 Mesh, Ted Pella,
Inc.). Grids were washed twice with sterile distilled water and then stained with uranyl acetate.
Grids were stored at room temperature with minimal exposure to light.
Prepared grids were imaged using a Zeiss 109 Transmission Electron Microscope with a
Kodak MegaPlus 1.6 Megapixel digital camera attachment. XCAP software for PC was used for
image processing and visualization.
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Prophage DNA Extraction and PCR amplification of Two Prophage Open Reading Frames
To determine whether or not viral particles were successfully produced following the UV
induction of strain Cuzco20, PCR was employed to amplify products from open reading frames
six and eleven of the prophage. Primers for H. pylori chromosomal gene Glucokinase were used
as a negative control to ensure absence of H. pylori DNA from samples. The HHMI Phage
Laboratory protocol “Isolate and Purify Phage Genomic DNA” (Appendix G) was utilized for
the extraction of bacteriophage DNA. A Sorvall RC6+ Centrifuge with HB-6 rotor was utilized
for centrifugation steps. PCR for the four previously mentioned genes was conducted as per the
Forsyth's Lab standardized protocol (Appendix H). Thermal cycler settings, primer names,
primer sequences, and primer melt temperatures are listed in Appendix B.
Briefly, filtered supernatants from induced H. pylori strain Cuzco20 cultures were transferred
to Falcon tubes. Nuclease Mix was added and the sample was incubated at 37° C for 30 minutes.
Following 37° C incubation, the sample was incubated at room temperature for one hour.
Following room temperature incubation, phage precipitant solution was added and the sample
was incubated overnight at 4° C. After overnight incubation, the sample was centrifuged at
10,000 x g for 20 minutes and supernatants were decanted. The viral pellet was resuspended in
sterile distilled water.
Following resuspension, “DNA Clean Up Resin” from Promega's “DNA Clean Up Kit” was
added. Using filter columns supplied in the Promega DNA Clean Up Kit, resin-treated samples
were pushed through said columns via syringe. 80% isopropanol was applied to the columns,
which were then centrifuged briefly. Using TE buffer, genomic DNA on the columns was eluted
via centrifugation and quantified using Dr. Oliver Kerscher's Thermo Scientific Nanodrop 1000
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S pectrophotometer.
PCR was run using primers for Glucokinase, orf6, and orfl 1, on Cuzco20 genomic DNA,
Induced Cuzco20 Filtered Supernatant, Purified Phage DNA from Control Induction sample, and
Purified Phage DNA from the 1.5mJ/cnr Induction sample. Briefly, samples were mixed with an
appropriate amount of New England Biolabs 6X blue gel loading dye and loaded into 1%
agarose gels containing ethidium bromide. New England Biolabs 1Kb and/or lOObp DNA
ladders were also utilized. Gels were suspended in .5X TAE in Thermo Scientific Owl Easycast
gel boxes. BioRad Power Pac 300 power supplies provided 100V of steady current for 30-45
minutes. Gels were imaged using a Kodak Gel Logic 100 Imaging System combined with a
Fisher Scientific UV Light box. Images were visualized and processed with Kodak Medical
Imaging software on an iMac.

Prophage Gene Expression in Induced Cultures
To investigate whether or not prophage genes are transcribed during antibiotic
induction, RT-PCR was utilized to detect the presence of bacteriophage RNA. Specifically,
strains J190 and J68 were induced using Mitomycin C as per the “Protocol for Induction of One
Helicobacter Pylori Strain” (Appendix J), described previously.
RNA extraction from induced samples of J190 and J68 was conducted using an Invitrogen
PureLink Micro-to-Midi Total RNA Purification System kit and manufacturer's protocol. RNA
quantification from purified samples was conducted using Dr. Oliver Kerscher's Thermo
Scientific Nanodrop 1000 Spectrophotometer. PCR was conducted, as previously described, on
purified samples using primers for Glucokinase and prophage integrase to confirm absence of
genomic DNA. Products were visualized via gel electrophoresis as previously described. DNA
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contamination was detected in all samples. DNase treatment was conducted on all samples as per
the Invitrogen kit's protocol “DNasel Treatment after RNA Purification.” PCR was again
conducted, as previously described, to confirm success of DNase treatment. DNA was detected
in all samples. “Rigorous” TURBO DNase treatment was conducted on all purified samples as
per the Invitrogen TURBO DNase Manufacturer's protocol. PCR and subsequent gel imaging
revealed DNA presence. Finally, Ambion Turbo DNase treatment was conducted on all samples,
as per the manufacturer's “TURBO DNA-free Second Digest Protocol.” PCR and subsequent gel
imaging revealed removal of all DNA from all samples.
Purified RNA from induced J190 and J68 cultures was utilized in Reverse Transcriptase PCR
reactions. Specifically, three master mixes were prepared, one for each of the Glucokinase, open
reading frame six, and integrase primer sets, as per the QIAGEN OneStep RT-PCR kit
manufacturer's protocol. An Applied Biosystems 2720 thermal cycler was used to run the
reactions. Annealing temperatures used for each primer set's thermal cycler program are listed in
Appendix B. Reaction products were visualized via gel electrophoresis. Briefly, samples were
mixed with an appropriate amount of New England Biolabs 6X blue gel loading dye and loaded
into 1% agarose gels containing ethidium bromide. New England Biolabs 1Kb and/or lOObp
DNA ladders were also utilized. Gels were suspended in 0.5X TAE in Thermo Scientific Owl
Easycast gel boxes. BioRad Power Pac 300 power supplies provided 100V of steady current for
30-45 minutes. Gels were imaged using a Kodak Gel Logic 100 Imaging System combined with a
Fisher Scientific UV Light box. Images were visualized and processed with Kodak Medical
Imaging software on an iMac.
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Design and Construction of Suicide Plasmid Vector pKAL2
In efforts to investigate the effects of prophage DNA presence on H. pylori, a suicide plasmid
vector was designed and constructed for use in transforming clinical isolate Cuzco20 in hopes of
creating a prophage knockout mutant. All primers mentioned in this section, along with their
melt temperatures and thermal cycler program settings, are described in detail in Appendix B. In
addition, Figure 1 below provides a schematic of primer locations and directionality with regard
to the prophage region of the Cuzco20 genome.

Cuzco20 Primer Schematic
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Figure 1. Schem atic o f Prim er Locations for Prophage R egion in Strain C uzco20. Schem atic depicts prophage sequence inserted in the intergenic
region betw een chrom osom al genes M etK and LpxD in strain Cuzco20. N um bers correspond to genom e location o f prim er start sites and
chrom osom e-prophage ju n ctio n s as per strain annotations in G enBank. Prim er nam es and relative directionality are indicated by colored nam es and
arrow s. Schem atic is not to scale.

Generation of pKAL
E. coli D H 5-a cells containing the pBluescript vector were obtained from Stephen Cole's 80° C freezer stock. Cells were passed onto a single L B -100 pg Ampicillin/ml agar plate and
incubated for 24 hours at 37° C. After 24 hours, three, 5mL LB-Ampicillin liquid broth stocks
were inoculated with cells harvested from the incubated plate. These liquid cultures were
incubated at 37° C for 24 hours in a non-C02 shaking incubator. Following incubation, mini-preps
were conducted on all three liquid cultures using an IBI High Speed Plasmid Mini kit. The
manufacturer's protocol was followed without modification. Eluted DNA from mini-preps was
quantified using Dr. Oliver Kerscher's Thermo Scientific NanoDrop 1000 Spectrophotometer.
Samples were stored at -20° C.
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Using Mac Vector software and Cuzco20 sequence data from GenBank, two primers sets
were designed to amplify regions 186 bp upstream and 336 bp downstream of the prophage in
Cuzco20. Specifically, the downstream primer set was composed of primers KAL.Rev.2 and
KAL.Fwd.2. The upstream primer set was composed of KAL.Rev. 1 and KAL.Fwd. 1. Four
cytosines, followed by a specific restriction site sequence, were incorporated into the 5' end
sequence of each primer. Specifically, KAL.Fwd.2 contains an EcoRl site. KAL.Rev.2 contains
an Xhol site. KAL.Fwd. 1 contains a BamHl site. Finally, KAL.Rev. 1 contains an EcoRl Site. All
primer sequences are available in Appendices B1 and B2.
Gradient PCR reactions using the upstream and downstream primer sets were conducted on
Cuzco20 genomic DNA, as per the Forsyth's Lab standardized protocol (Appendix H) using a
Labnet MultiGene thermal cycler, to determine optimal annealing temperatures. Reaction
products were visualized via gel electrophoresis as previously described.
Amplified DNA from the gradient PCR reactions previously described was purified using an
LBI Gel/PCR DNA Fragment Extraction Kit. The manufacturer's protocol was followed without
modification. Purified DNA was quantified using Dr. Oliver Kerscher's Thermo Scientific
NanoDrop 1000 Spectrophotometer. Purified DNA was visualized via gel electrophoresis, as
previously described, to verify product integrity. Specifically, 904bp and 778bp bands should be
present for the upstream and downstream primer set products, respectively.
Purified pBluescript vector, previously purified from DH5-0C E. coli cells, was digested for
two hours at 37° C with both BamHl and EcoRl restriction enzymes in lOx EcoRl-specific
buffer, as per New England Biolabs recommended protocol (Appendix N). It is important to note
that New England Biolabs restriction enzymes are not designed to be used in dual-enzyme
overnight digestions. Use of two enzymes simultaneously in an overnight digestion reaction risks

30

star activity. After incubation, the digested sample was quantified using Dr. Oliver Kerscher's
Thermo Scientific NanoDrop 1000 Spectrophotometer and stored at -20° C.
Purified Upstream product (904bp) from the Cuzco20 genomic DNA gradient PCR was
digested for 2 hours at 37° C with both BamHl and FcoRI restriction enzymes in lOx EcoBlspecific buffer, as per New England Biolabs recommended protocol (Appendix N). After
incubation, the digested sample was quantified using Dr. Oliver Kerscher's Thermo Scientific
NanoDrop 1000 Spectrophotometer and stored at -20° C .
Both the Upstream product and pBluescript digest samples were purified using an IBI
Gel/PCR DNA Fragment Extraction Kit, following the manufactures protocol with no
modifications.
As per Dr. Mark Forsyth's recommended ligation reaction protocol, the following were
combined in a microcentrifuge tube and placed in a 16° C heat block (located in a 4° C
refrigerator) overnight: 1 Jill lOx Ligase Buffer, 1 j il T4 DNALigase, 2 (al purified
itaraHFFcoRI-digested pBluescript plasmid, and 6 (il purified ZtaraHI/FcoRI-digested Upstream
PCR product.
The ligation reaction product was transformed into JM109 competent E. coli cells as per Dr.
Mark Forsyth's protocol “Transformation of JM109 Cells” (Appendix M). Transformation
reactions plated onto FB-Ampicillin/X-GAF agar plates were incubated overnight at 37° C in a
non-CCF incubator.
Six, 5mF aliquots of FB-Ampicillin broth were each inoculated with one white colony
picked from the previously mentioned transformation reaction plates. Fiquid cultures were
incubated, rotating, at 37° C for 24 hours. After incubation, mini-preps were conducted on all six
cultures using an IBI High Speed Plasmid Mini kit. The manufacturer's protocol was followed
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without modification. Mini-prep products were stored at -20° C.
Dual-restriction digests of aliquots from all six mini-prep products were conducted using
New England Biolabs BamHl and EcoRl restriction enzymes as previously described. Digested
products were visualized via gel electrophoresis, as previously described, to confirm the presence
of two bands (pBluescript vector and Upstream PCR product).

Generation of pKALl
Dual-restriction digests of aliquots from all six mini-prep products were repeated using New
England Biolabs Xhol and EcoRl restriction enzymes as previously described. Additionally,
purified downstream product (778 bp) from the H. pylori strain Cuzco20 genomic DNA gradient
PCR was digested for 2 hours at 37° C with both Xhol and EcoRl restriction enzymes in lOx
EcoRI-specific buffer, as per New England Biolabs recommended protocol (Appendix N). After
incubation, the digested samples were quantified using Dr. Oliver Kerscher's Thermo Scientific
NanoDrop 1000 Spectrophotometer. Immediately following quantification, aliquots of each
digest were combined in a ligation reaction. Specifically, as per Dr. Mark Forsyth's
recommended ligation reaction protocol, the following were combined in a microcentrifuge tube
and placed in a 16° C heat block (located in a 4°C refrigerator) overnight: lpD lOx Ligase
Buffer, l|iL T4 DNA Ligase, 2jaL purified X/zoI/ZscoRI-digested pBluescript plasmid, and 6 (iL
purified XhoUEcoRl-digested Downstream PCR product.
After overnight incubation, the ligation reaction product was transformed into JM109
competent E. coli cells as per Dr. Mark Forsyth's protocol “Transformation of JM109 Cells”
(Appendix M). Transformation reactions plated onto LB-Ampicillin/X-GAL agar plates were
incubated overnight at 37° C in a non-C02 incubator. Previous insertion of the Upstream PCR
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product into the pBluescript vector, and subsequent interruption of the beta-galactosidase gene,
resulted in a loss of blue-white color selection. All colonies should appear white.
Ten, 5mL aliquots of LB-Ampicillin broth were each inoculated with a single, randomly
selected white colony from the previously described transformation plates. These liquid cultures
were incubated overnight. After overnight growth, liquid cultures were mini-prepped using an
IBI High Speed Plasmid Mini kit. The manufacturer's protocol was followed without
modification. Mini-prep products were stored at -20° C.
Aliquots from all ten mini-prepped samples were digested with X hol and EcoRl restriction
enzymes as previously described. Digestions products were visualized via gel electrophoresis, as
previously described, to identify samples containing both upstream and downstream inserts.
After identification of a mini-prepped sample containing the pBluescript plasmid containing
both the upstream and downstream inserts, cells from the original transformation source colony
were used to inoculate 5mL of LB-Ampicillin broth. This liquid culture was placed overnight in
a non-CCE rotating incubator at 37° C. After overnight growth, a lm L aliquot was taken from the
liquid culture. Glycerol was added to 20% in the lm L aliquot, which was then frozen at -80°C.
The plasmid contained in this freezer stock was deemed “pK A L l”. pKALl is composed of the
pBluescript vector combined with the regions upstream and downstream of the prophage from
strain Cuzco20, as previously described.

Generation of pKAL2
Separately, 5mL of LB-Ampicillin broth was inoculated with E. coli cells containing plasmid
pUC4K (which contains a resistance gene to the antibiotic Kanamycin). Inoculated cultures were
incubated overnight at 37° C in a rotating non-CCb incubator. After incubation, the liquid culture
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was mini-prepped using an IBI High Speed Plasmid Mini kit. The manufacturer's protocol was
followed without modification. The mini-prep product was stored at -20° C.
Two separate, EcoRl restriction digests were conducted on the pKALl and pUC4K plasmids
in microcentrifuge tubes. Specifically, 10 pL of each plasmid was combined with 3pL of lOx
EcoRl buffer, 3 pi of EcoRl restriction enzyme, and 14 pi of sdH20, for a total volume of 30 pi.
Each restriction digest was incubated overnight at 37° C. After overnight incubation, 8 pi of
pK A Ll digest was combined with luL of Shrimp Alkaline Phosphatase (SAP) buffer and 1 pi of
Shrimp Alkaline Phosphatase in a microcentrifuge tube. The mixture was incubated in a 37° C
water bath for one hour, then heat inactivated at 75° C for 20 minutes.
Both the SAP-treated pKALl digest sample and the pUC4K digest sample were visualized
via gel electrophoresis, as previously described. Using an IBI Gel/PCR DNA Fragment
Extraction Kit and following the manufacturer's protocol without modification, the
approximately 1.2 kb Kan resistance gene band was purified from the gel. Following purification
of the band, two identical ligation reactions were conducted by combining the following in
microcentrifuge tubes: 1 pi 1Ox Ligase Buffer, 1 pi T4 DNA Ligase, 2 pi Purified, SAP-treated,
EcoRI-digested pK A Ll, 6 pi gel-purified, Kan resistance gene from pUC4K. Each identical
reaction was placed in a 16° C heat block (located in a 4° C refrigerator) overnight.
After overnight incubation, the ligation reaction products were transformed into JM109
competent E. coli cells as per Dr. Mark Forsyth's protocol “Transformation of JM109 Cells”
(Appendix M). Transformation reactions were plated onto six LB-Ampicillin-Kanamycin agar
plates (three plates per ligation reaction) and incubated overnight at 37° C in a non-CCL incubator.
After overnight incubation, four visible colonies were picked and used to inoculate four separate
5mL LB-Ampicillin-Kanamycin broth stocks. These liquid cultures were incubated at 37° C in a
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non-C02 rotating incubator. In addition, prior to inoculation but after picking, each colony was
touched to a gridded LB-Ampicillin-Kanamycin agar plate and placed in a 37° C non-CCb
incubator.
After overnight growth, all four liquid cultures (excepting 2mL aliquots from each culture to
which 20% glycerol was added for freezer stock storage at -80° C) were mini-prepped using an
IBI High Speed Plasmid Mini kit. The manufacturer's protocol was followed without
modification. Mini-prep products were stored at -20° C. The mini-prepped plasmid product
generated from these procedures, containing the pBluescript vector, upstream and downstream
PCR products, and the Kanamycin resistance gene, were deemed pKAL2.
PCR reactions were conducted on purified pK A Ll and pKAL2, as previously described,
using the following four primer sets to confirm the presence of each suicide vector component:
KAL.Rev. 1 and KAL.Fwd.2, KAL.Fwd. 1 and KAL.Rev.2, KAL.Rev. 1 and KAL.Rev.2, and
KAL.Fwd. 1 and KAL.Fwd.2.
Finally, to confirm the proper orientation of pKAL2 vector components, two sequencing
primers were designed and named KAL.Rev.3 and KAL.Fwd.3. Seven, 5-mL aliquots of LBAmpicillin-Kanamycin broth were inoculated with E. coli containing pKAL2 and grown
overnight at 37° C in a non-C02 rotating incubator. Five of the seven cultures were mini-prepped
using an IBI High Speed Plasmid Mini kit. The manufacturer's protocol was followed without
modification. Mini-prep products were stored at -20° C. The remaining two liquid cultures were
divided into lm L aliquots and mixed with glycerol to a final concentration of 20% and stored at 80° C.
Following the Forsyth Lab's “Big Dye Sequencing and DTR Gel Cartridge Purification”
(Appendix K) protocol (without modification) on purified pKAL2, and utilizing primers
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KAL.Fwd.3 and KAL.Rev.3 in two separate reactions, the pKAL2 plasmid was prepared for
sequencing. Following the speed vacuum component of the protocol, samples were stored at -20°
C. Samples were submitted to Lidia Epp in William and Mary's Biology Department for
sequencing via the Sanger method. Sequencing results confirmed the proper orientation of the
Upstream and downstream PCR products, as well as the Kanamycin resistance gene, in the
pBluescript vector.
Following the Forsyth Lab's “Big Dye Sequencing and DTR Gel Cartridge Purification”
(Appendix K) protocol (without modification) on purified pKAL2, and utilizing primers T3, and
T7, two separate sequencing reactions were conducted. Following the DTR gel cartridge
purification and speed vacuum steps, samples were submitted to Lidia Epp in William and
Mary's Biology Department for sequencing via the Sanger method. Sequencing results confirmed
the proper orientation of the Upstream and Downstream PCR products in the pBluescript vector.

Attempted Transformations of pKAL2 into H. pylori strain Cuzco20
Following the Forsyth Lab's protocol “Natural Transformation of H. pylori” (Appendix L)
(without modification) and utilizing strain Cuzco20 and purified plasmid pKAL2, an attempt a
transformation was made. After failure to observe visible colonies on transformation plates, the
protocol was repeated two times. The second and third attempts at transformation of Cuzco20
with pKAL2 were also unsuccessful.
Utilizing an in vitro methylation protocol adapted from J.P. Donahue, 2009 (Appendix I),
plasmid pKAL2 was treated. Following methylation, pKAL2 transformation into Cuzco20 was
again attempted using the Forsyth Lab protocol “Natural Transformation of H. p ylo ri”
(Appendix L). This transformation was also unsuccessful.
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Results and Discussion
PCR Screening Reveals Trends in Prophage Presence and Insertion Location
To examine the presence, completeness, and insertion site locations of prophage in clinical
isolates, PCR screening was employed. Results from this screening revealed several important
trends. Examples of PCR results from interrogation of the IpxD/metK region of the genome, as
well as prophage open reading frames 11, 13, 17, and 27, are provided in Figure 2 and Figure 3.
A full summary of all collected data from the battery screening is available in Appendix 1, Table
SI.
Briefly, screening for the presence of the H. pylori prophage integrase gene revealed a
significant positive correlation with cag PAI (-) strains. This was surprising because in many
classically cited studies, prophage tend to be associated with more virulent strains of human
bacterial pathogens. Examples include the bacterial species responsible for hemorrhagic diarrhea
(shiga-toxin-producing E. coli), cholera (cholera-toxin-producing V. cholerae), and botulism
(botulinum-toxin-producing C. botulinum). Subsequent screening of H. pylori isolates for the
presence of prophage open reading frame six revealed an identical trend (Table SI).
Based on previous sequence data for H. pylori strain J68 from our lab, it was known that
prophage sequence in J68 was inserted in the middle of the coding region for the chromosomal
gene HP0453 (function unknown). Data from screening our battery of H. pylori clinical isolates,
combined with BLASTp, BLASTx, and BLASTn searches, revealed that interestingly,
chromosomal gene HP0453 is found in 74% of cagPAl (-) strains (n=23) but only 13% of
cagPAI(+) strains (n=60). Furthermore, screening our clinical isolates using primers designed to
amplify a product across the H. pylori strain J68 prophage-chromsome junction point
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(H P 0 4 5 3 x o rf2 ) indicated that prophage insertion in this location was again nearly exclusive to
cag PAI (-) strains (Tables 1 and SI). This high degree of consistency in bacteriophage
recombination site locations in a single species is unsurprising.
Based on sequence data available in GenBank, it was known that prophage sequence in the
cag PAI(+) strain Cuzco20 is inserted in an intergenic region between chromosomal genes IpxD
and rnetK encoding UDP-3-0-[3-hydroxymyristoyl] glucosamine N-acyltransferase and Sadenosylmethionine synthetase, respectively. PCR screens for each of these two chromosomal
genes, as well as for an amplicon spanning the junction of the two genes (Ip x D x m e tK ),
indicated complete exclusivity of prophage insertion in this site to cag PAI(+) strains (Table SI).
However, unlike gene HP0453, IpxD and metK are present in nearly all strains (Table 1) of H.
pylori, regardless of cag PAI status.
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Figure 2. Gel Electrophoresis of Products from Three PCR Screens of the IpxD/metK Insertion Point. The
image above depicts reaction products from three separate reactions involving primer sets for IpxD, metK, and
the junction between IpxD and metK. Samples were run for 35 minutes at 100V on a 1% agarose gel. Products
from control strains Cuzco20 and J99 were run in lanes 24, 32, 40 and 25 and 4, respectively. Water control
samples were run in lanes 26, 33, and 42. Lanes labeled 1-23 contained IpxD >< metK junction products from
cag PAI(-) strains. Lanes 27-31 contain products from cag PAI (+) strains screened with IpxD primers. Lanes
34-39 contain products from cag PAI (+) strains screened with m etK primers. Results provide evidence
supporting the observation that prophage DNA insertion does not occur m etK the IpxD >< metK intergenic
region in cag PAI (-) strains.
Table 1. Summary of Selected PCR Results. Table detailing number of isolates successfully amplifying a PCR
product, expressed in percentages of either cag PAI (-) or cag PAI (+) isolates. N values indicate total number of
strains in each of the two screening groups (cag PAI (-) or cag PAI (+)). P values were calculated using chisquare analysis. Bold font denotes significance (p < .05). “Prophage” row indicates successful amplification of
at least three out of four prophage gene markers.

Partial screening of the H. pylori isolate battery with consensus primers for open reading
frames 11, 13, 17, and 23 revealed presence of possible incomplete prophage in two cag PAI(+)
strains. H. pylori cag PAI (-) strain B238a possesses each of these four prophage open reading
frames, suggesting the presence of a complete prophage sequence. A sample of the screening
results are shown in Figure 3.
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Figure 3. Gel Electrophoresis of Products from Four PCR Reactions Screening for Prophage ORFs. The
image above depicts reaction products from four separate PCR reactions involving primer sets for prophage
open reading frames 11, 13, 17, and 23. Samples were run for 35 minutes at 100V on a 1% Agarose gel.
Prophage open reading frames are indicated at the top of each lane, while source strain genomic DNA is
indicated at the bottom. Results indicated that strains J178 and 87-81 possess open reading frames 17 and 23 of
the prophage. Strain B238a possesses open reading frames 11, 13, 17, and 23. Though a faint band for open
reading frame 23 is present for strain B80, it does not conclusively possess any of the four prophage open
reading frames.

Overall, screening results indicate that H. pylori gene HP0453 and prophage sequence
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presence are significantly associated with the absence of cag Pathogenicity Island. Following
M aurelli’s definitions, it is possible that gene HP0453 is an antivirulence gene and is thus under
negative selective pressure when present in cag PAI (+) H. pylori isolates (26). Regarding
prophage sequence insertion locations, it is clear that preferential insertion occurs in the HP0453
coding region in cag PAI(-) strains and in the intergenic region of IpxD and metK in cag PAI(+)
strains.

Characterization of Prophage Completeness in Sequenced Strains
Over 30 sequenced Helicobacter strains were compared using GenBank data and NCBI
tools. A bias towards analysis of cag PAI(+) strains is inherent in comparing H. pylori sequences
due to the fact that sources of clinical isolates are often patients presenting with severe disease.
Additionally, there is greater interest overall in the investigation of more pathogenic strains of
the bacterium. A summary of the accumulated bioinformatic data is presented in schematic form
in Figure 4 below.
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Figure 4. Schematic of Prophage Insertion Locations. Schematic of six different prophage sequence locations
in two Helicobacter species. Specifically, strain Sheeba* is an isolate of the species Helicobacter acinonychis,
while all other strains are H elicobacter pylori. Chromosomal genes are indicated by black coloration and
presence of a gene name. Non-black arrow coloration indicates prophage sequence. Chromosomal gene arrows
are not to scale. H. pylori strain J68 prophage sequence interrupts chromosomal gene HP0453; determination of
sequence downstream of prophage orf7 is in progress. Cuzco20, Shil 12, Gambia94/24, and India7 possess
prophage sequence cleanly inserted between chromosomal genes IpxD and metK. Strains F I 6, B45, J68, and
B38 possess prophage sequence of varying completeness in unique locations. Helicobacter acinoncychis strain
Sheeba possesses the entire prophaee sequence in a unique location.

Comparisons revealed significant variety in observed prophage insertion locations among
sequenced cag PAI(+) strains. Specifically, three different insertion sites were identified.
Interestingly, this runs counter to the single-site insertion trend in cag PAI (-) H. pylori isolates
observed via PCR screening. Furthermore, only six of the 30 sequenced cag PAI(+) strains
possessed any portion of this prophage, supporting the observation that the prophage is
significantly more likely to found in cag PAI(-) strains. Of these six strains, prophage sequence
was shown to be inserted in the IpxD/metK intergenic region in four cases. Of additional interest
is the observation that no prophage sequences are inserted in tRNA genes, the preferred
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integration sites for the majority of bacteriophage (32).
Regarding completeness of prophage sequence, only two of the sequenced H. pylori strains
possessed all 32 prophage open reading frames. Interestingly, strains possessing incomplete
prophage showed deletions from both ends of prophage sequence, centering roughly around the
large, mosaic-protein-encoding open reading eleven. Additionally, incomplete prophage
sequence was often bordered on one side by sequence coding for transposases, hinting at a
probable cause of sequence degradation.

Characterization of IpxD/metK Intergenic Regions
Due to the discovery that the majority of prophage-harboring cag PAI(+) strains show
insertion of viral sequence in the IpxD/metK intergenic region, further analysis was conducted.
Sequence homologies between these strains were identified. Results from the analysis are
presented in schematic form in Figure 5 below.
Briefly, the unoccupied empty-site intergenic region is 64 bp in length. Strains possessing full
prophage sequence in this location increase the distance between IpxD and metK to almost 30 kb.
Our sequence analysis of genomic data within publically available databases revealed the
presence of a 164 bp IpxD/metK intergenic region in H. pylori strain Pecan 18. Comparison of
Pecan 18 to both strains harboring prophage in this location and empty-site strains revealed
sequence homology. Specifically, duplication of insertion site sequence characteristic of
bacteriophage integration was observed. In addition, Pecan 18 harbors sequence in this region
homologous to duplicated sequence directly bordering prophage coding regions. Taken together,
this data indicates that Pecan 18 likely harbored a prophage that was excised but defective, failing
to lyse the cell and leaving a hallmark of phage excision behind. Additional sequence
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comparisons in this reasons revealed a potential att recombination site sequence (indicated by
red coloration in Figure 5).
*lnterg<»nic region conserved
among 32 sequenced strains m
NC6I database containing empty
site

64bp'

*26695
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Hedc I
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Figure 5. Schematic of Selected IpxD/metK Intergenic Regions and Prophage Insertion Sites. * indicates
identical empty site present in H. pylori strain 26695 and 31 other GenBank sequenced strains of H. pylori.
Regions of identical coloration correspond to approximately identical sequence. Boxed areas containing
diagonal lines indicate regions of prophage sequence and are not to scale. Delta symbol denotes deletion of
indicated prophage open reading frames.

Microscopy Indicates Presence of Virus-Like Particles
Informed by PCR and sequence data indicating the presence of prophage in multiple
isolates from our collection, inductions using Mitomycin C and UV irradiation were conducted
on H. pylori strains 194a, 26695, B186a, Cuzco20, J68, J150, and B238a, as well as H.
acinonychis strain Sheeba. Strain 26695 was used as a negative control because its GenBank
sequence indicated the complete absence of the prophage. Epifluorescence and Transmission
Electron (TEM) microscopy were used to visualize filtered supernatants from induced cultures.
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Images from several strains indicated the presence of virus-like particles. This data supports
recently published information regarding successful induction and imaging of bacteriophage
particles from different strains of Helicobacter pylori (46-48). Specifically, epifluorescence
images from UV and Mitomycin C-treated H. pylori strains Cuzco20 and H. acinonychis strain
Sheeba showed presence of virus-sized particles. Further analysis via TEM showed darkly
stained particles approximately 100 nm in diameter. Particles did not possess recognizable tails,
and were approximately icosahedral in their geometry. In addition to these two strains, TEM
images of filtered supernatants from an induced sample of H. pylori strain B238a showed similar
phage-like particles. Epifluorescence and TEM images from control strain 26695 did not reveal
the presence of phage-like particles, indicating that the particles seen from other strains were not
likely to be artifacts. Images from induced J150 yielded ambiguous results. Finally, images from
induced strains 194a and J68 were negative for the presence of phage-like particles. A selection
of microscopy images is presented in Figure 6 below.
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Figure 6. Epifluorescence and TEM Images of Induced H elicobacter strains. A-C. Epifluorescence images
(l,000x magnification) o f SYBR Gold-stained, UV-induced, H. pylori Cuzco20 Control, 1.5mJ/cm2 UV[rradiated, and 2.5mJ/cm2 UV-irradiated samples,respectively. D-F. Transmission Electron Microscopy images
(85,000x magnification) of negatively-stained, 2.5mJ/cm2 UV-irradiated B238a, Cuzco20, and Helicobacter
acinonychis (Sheeba) samples, respectively. Epifluorescence images indicate presence of viral-sized particles in
all samples. TEM images indicate presence of tail-less, viral-sized particles, with tentative icosahedral
morphology, in all samples.

In light of the recently published study by Luo et al. showing viral particles induced from H.
pylori exhibiting characteristic Podoviridae morphology, it is possible that failure to visualize
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tails in our samples was due to a combination of poor imaging and heavy staining, obscuring the
potentially small tails (48). Due to the ambiguity of our TEM imaging results, we cannot
absolutely confirm the presence of viral particles in our samples. However, recent data supports
UV irradiation and Mitomycin C as successful means of induction for strains of H. pylori. Taken
together, epifluorescence and TEM imaging data, suggest that viral particles may be induced
from H. pylori lysogens.

Amplification of Phage DNA and Detection of Phage RNA Has Been Unsuccessful To Date.
As an alternative to microscopy, RT-PCR and PCR techniques were employed to
investigate whether induction of viral particles from H. pylori strains was successful.
Specifically, two separate experiments were conducted. The first analyzed samples from one UV
induction of Cuzco20 for the presence of viral DNA via PCR for prophage open reading frames
six and eleven. The second analyzed samples from Mitomycin C inductions of strains J 190 and
J68 for the successful transcription of prophage genes integrase and orf '6.
The gel image shown below in Figure 7 indicates that viral DNA was not present in cellfree, UV-induced samples of H. pylori strain Cuzco20. Considering the low density of virus-like
particles observed using microscopy, it is possible that initial phage titers in samples were too
low for detection. Additionally, it is possible that a low starting titer resulted in the complete loss
of DNA during the extensive purification and isolation steps. However, due to the sensitivity of
PCR, and the proper use of positive and negative controls, it seems likely that the sample did not
contain viral DNA.
Investigation of orf6 and integrase transcription via RT-PCR in Mitomycin C-induced H.
pylori strains of J 190 and J68 yielded similar results. Figure 8 indicates no transcription of either
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prophage open reading frame. The success of the positive glucokinase control indicates
successful initial extraction of RN Afrom samples and generation of cDNA. Additionally, the
absence of phage-like particles from microscopy images of Mitomycin C-induced samples of
strain J68 support these results. Taken together, this indicates that the prophage was not
successfully induced from either J 190 or J68. However, it is possible that neither integrase nor
orf6 open reading frames are transcribed during excision of prophage DNA, viral particle
construction, or cell lysis. In addition, the use of Mitomycin C as an inducing agent might not
have been effective at the dose utilized.
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Figure 7. Gel Electrophoresis of Products from Three PCR Reactions Screening for Prophage DNA
Extracted from Induced Cultures. The image above depicts reaction products from three separate PCR
reactions involving primer sets for Glucokinase and prophage open reading frames six and eleven. Samples
were run for 35 minutes at 100V on a 1% Agarose gel. Lanes designated “ 1” contain Cuzco20 genomic DNA.
Lanes designated “2” contain 0.22 micron-filtered supernatant from a Cuzco20 XI UV induction sample. Lanes
designated “3” and “4” contain purified putative bacteriophage DNA from Cuzco20 Control and XI UV
induction samples, respectively. Lanes designated “5” contain water controls. Results indicate amplification of
positive controls for each primer set. No prophage DNA from any of the experimental samples was amplified.
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Figure 8. RT-PCR Amplicons from H. pylori J68 & J190 Mitomycin C Inductions. Prophage induction
protocols using Mitomycin C were executed for strains J190 and J68. Extracted and purified RNA from all
samples was reverse transcribed and amplified using primers for Gluckokinase (GK, positive control) and
prophage genes Integrase (Int) and orf6. Reaction products were visualized via gel electrophoresis as previously
described. To enhance comparative accuracy, the same three PCR products amplified from J68 genomic DNA
were run four times on the gel adjacent to each experimental group. These identical products are highlighted in
yellow. Results indicate proper amplification of positive controls. Prophage RNA, from either Integrase or orf6,
was not present.

The failure of both experiments to amplify viral nucleic acids does not agree with the
current literature on H. pylori inductions or our imaging data indicating presence of virus-like
particles (46-48). Future experiments should utilize both methods of induction, and additional
prophage open reading frames should be interrogated.

Successful Construction of Plasmid Vector pKAL2
In efforts to better characterize the effects of prophage DNA presence on host H. pylori
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strains, the creation of a suicide plasmid vector was undertaken. Experiments confirming the
proper construction of the vector, pKAL2, and built from a pBluescript vector template, were
successful. Specifically, multiple PCR and sequencing reactions confirmed the presence and
orientation of the upstream and downstream amplicons from H. pylori Cuzco20, and the
Kanamycin resistance gene (aphA3) from pUC4K. An example of the results from one such
experiment and a schematic of the complete vector are provided in Figures 9 and 10 below.
Sequence data is provided in Figure S2 in Appendix 1.
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Figure 9. Gel Electrophoresis of Products from Four PCR Reactions Screening for Presence of Kanamycin
Resistance Gene in pKAL2. The image above depicts reaction products from four separate PCR reactions
involving primer sets from the design of vector pKAL2. Samples were run for 35 minutes at 100V on a 1%
Agarose gel. Yellow lanes contain purified pKA Ll DNA. Green lanes contain purified pKAL2 DNA. Blue lanes
contain water controls. Results from primer set KAL.Fwd.l + KAL.Rev.2 (lower-left quadrant) indicate a size
shift of approximately 1,200 bp between vectors pKALl and pKAL2. This provides evidence of the incorporation
and proper orientation of the Kanamycin resistance gene in vector pKAL2.
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Figure 10. Schematic of Suicide Plasmid Vector pKAL2 and Expected Homologous Recombination
Event in Cuzco20. A. Major genes, total length, and restriction sites are indicated. Regions referred to as
“upstream’" and “downstream ” of prophage indicated sequence source location relative to Cuzco20 prophage.
B. Depiction of expected homologous recombination event in strain Cuzco20. Black lines indicate
chromosomal sequence. Blue lines indicate homologous chromosomal and plasmid sequence. Yellow line
indicates prophage sequence. Red line indicates Kanamycin resistance gene.
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Transformations of pKAL2 into H. pylori Cuzco20 Are Unsuccessful
Despite the use of in vitro methylation techniques and multiple attempts at transformation of
pKAL2 into strain H. pylori Cuzco20 to delete the prophage, no knockout mutants were
generated. In addition, attempts at transformation of strain Cuzco20 using a control pCTB8:Kan
vector, a positive control plasmid for allelic replacement of the vacA locus, were also
unsuccessful. The failure of the pCTB8::Kan control to incorporate into the vacA locus in H.
pylori strain Cuzco20 may be due to the heterologous nature of the vacA sequence in the
plasmid. This plasmid was constructed using vacA sequence from H. pylori strain 60190 (50).
Regarding the failures of pKAL2 transformations, one likely cause is the size of the locus
targeted for deletion. A recombination event on the order of 30,000 bp in magnitude, combined
with individual strain variation in H. pylori and non-lab-adapted nature of Cuzco20, are
significant barriers. However, previously published data demonstrates the successful use of a
suicide plasmid vector in the deletion of the entire cag Pathogenecity Island from an H. pylori
isolate. Current efforts are aimed at designing a set of new suicide plasmid vectors to delete the
prophage in sections. We hope that the decrease in target locus size will increase the likelihood
of a successful recombination event.

Future Directions
Though this thesis represents significant progress towards understanding the nature of
prophage in strains of Helicobacter pylori, additional investigation is warranted. Several
experimental tracks are proposed below that would provide a clearer picture of the dynamics of
prophage induction, effects of prophage on bacterial host gene expression, and varied prophage
insertion locations in H. pylori ’s chromosome.
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Investigation of Prophage Excision from IpxD/metK Intergenic Region
Regarding the frequently observed insertion of prophage genes in the intergenic region
between chromsomal genes IpxD and metK, an alternative means of assessing successful
induction and subsequent excision of prophage sequence is needed. Thus far, plaque assays using
multiple prophage-positive strains have yielded negative results. Additionally, TEM images have
not been definitive. Therefore, strains identified as having prophage sequence inserted in
between IpxD and metK should be investigated by cultivating them, passing some of the culture
to new plates and conducting gDNA extractions on the remaining cells. PCR reactions would be
run using the extracted gDNA with primers amplifying between IpxD and metK. Cultures
originating from the passed strains would undergo UV induction as previously described.
Following induction, a second gDNA extraction would be conducted on the induced cultures,
and PCR reactions with primers designed to amplify a product between the two chromosomal
genes IpxD and metK run. Any strain that failed to produce an amplicon during the pre-induction
PCR but that did produce an amplicon post-induction would demonstrate successful excision of
phage DNA.

Continued Battery Screening Using Primers for Prophage Open Reading Frames
Though a large number of strains were screened and new primers designed for the
amplification of prophage open reading frames, much work remains to be done. The continued
screening of battery strains for additional prophage open reading frames using currentlyavailable primers would broaden this project’s sample size and could increase the statistical
significance of observed prophage completeness and insertion trends. Furthermore, the use of in
silico PCR, using the same primers, on sequenced NCBI database strains could compliment data
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from Dr. Forsyth’s strain collection.

Sequencing of Insertion Locations
The falling cost of sequencing makes investigating the genomes of screened battery strains a
reasonable endeavor. Though whole-genome sequencing would be ideal, even smaller
sequencing reactions could be used to examine sites of interest. Specifically, known prophage
insertion locations and their surrounding sequences would be a primary focus. For example,
comparing the sequence of chromosomal gene HP0453 from strains that possess or lack the
prophage would assist in determining sequence modifications that may be responsible for
mediating prophage insertion. Additionally, comparison of sequence from different insertion
sites, such as comparing the intergenic region of IpxD and metK with HP0453, would also assist
in understanding sequences specific to mediating prophage insertion.

High Temperature Growth Conditions as a Potential Prophage Inducer
Though UV and antibiotic inductions have been attempted, it would be useful to investigate
other cell stressors that might provoke viral particle production in strains harboring prophage.
Specifically, using high incubator temperatures during cell culturing would be a simple
alternative. Strains could be cultivated at a variety of temperature above 37 degrees Celsius and
assessed for viral particle production via epifluorescence and transmission electron microscopy,
as previously described.

Continued Screening of Induced Strains Using RT-PCR
Several pilot RT-PCR experiments were conducted with varying degrees of success.
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Importantly, the most recent of these experiments yielded data confirming transcription of
several prophage open reading frames in strain Cuzco20. Repeating these experiments using
additional prophage-positive strains would provide another layer of information regarding the
activity of prophage genes. Ideally, transcription of prophage genes could be shown to vary
depending on whether or not a strain harboring those genes had undergone induction.
Additionally, expansion of the RT-PCR experiments to include both new prophage-positive
strains and screening of more prophage open reading frames would provide a more
comprehensive picture of prophage gene expression.

Deletion of Prophage Sequence Using Modified Suicide Plasmids
Though deletion of the entire prophage sequence in strain Cuzco20 has not yet been
successful using the pKALl vector, modifications to the existing protocol might achieve
deletion. As previously mentioned, it is likely that the large size of the prophage sequence
(~30kb) in Cuzco20 is prohibitive to a single large recombination event. Therefore, it might be
useful to create multiple suicide plasmid constructs, each designed to remove only a portion of
prophage sequence, which could be used in successive recombination events. Theoretically, these
smaller recombination events would be more likely to occur than one large event, and would
allow for the deletion of the prophage sequence piece-by-piece. Additionally, the use of
alternative, non-Kanamycin antibiotic resistance markers should be considered.

Motility Assays Using a Prophage Knockout Mutant
Provided that a successful prophage knockout mutant could be generated from Cuzco20, two
experiments could be conducted examining clinically-relevant characteristics of the mutant.
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First, considering the importance of pH during H. pylori colonization of its human host, pH
sensitivity assays would help elucidate if the presence or absence of prophage sequence modifies
the bacterium’s survivable environmental pH range. Simply growing a prophage knockout strain
on plates containing media of varying acidity and comparing growth rates to a control strain
would provide basic sensitivity data. Secondly, due to H. p y lo n ’s need to maneuver through the
thick mucosal layer of the human stomach during colonization, conducting motility assays on a
Cuzco20 knockout mutant could prove useful in quantifying larger-scale effects of prophage
presence or absence. Culturing H. pylori control and knockout mutant strains in agar and
comparing migration distances during growth would provide a straightforward means of
assessing if motility is altered by the presence or absence of prophage sequence.

Concluding Remarks
Helicobacter pylori is a widespread and important human pathogen. Though it infects half of
the world’s population and has been studied for decades, there are many aspects of the bacterium
that remain poorly characterized. The rise of antibiotic resistance in H. pylori strains and data
demonstrating the multitude of clinically-relevant effects caused by prophage presence in other
bacterial human pathogens highlight an important need for a better understanding of hostprophage dynamics in H. pylori. Using PCR screening data, coupled with an analysis of
sequenced strains, we have revealed novel trends in H. pylori related to cag PAI status and the
presence, location, and completeness of prophage. The significant association of prophage with
H. pylori cagPAl (-) strains runs counter to traditional observations in the context of the
relationships between human bacterial pathogens and bacteriophage. Additionally, the lack of
prophage insertion site variation in cag PAI(-) strains provides an interesting juxtaposition to the
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uncommon, somewhat promiscuous insertion behavior observed in cag PAI(+) strains.
Combined with recently published data on prophage induction in H. pylori, our imaging data
tentatively support the successful induction of bacteriophage from our clinical isolates. Further
PCR and RT-PCR experiments, along with inductions, will be required to provide conclusive
evidence for induction. Additionally, the generation of a prophage knockout mutant will prove
invaluable in investigating the effects of prophage presence on host gene expression. Taken
together, this data contributes to a broader understanding of H. pylori genomic heterogeneity and
reveals novel trends in bacteriophage lysogenic behavior.

Appendix 1
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Figure SI. Gel Electrophoresis of PCR Products from H P 4 5 3 x o r f2 Junction Screen. The image above
depicts reaction products from a PCR reaction utilizing primers for the junction of H.Pylori chromosomal gene
HP0453 and orf2 of the prophage. Samples were run for 35 minutes at 100V on a 1% Agarose gel. Possession
of the cag PAI by a strain is indicated by a (+) or a (-). J68 (highlighted) is the positive control; water is the
negative. Results indicate insertion of prophage sequence in the coding region of gene HP0453 in strains B240a,
B102, B212, J190. and J68.
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Table SI. Summary of Collected PCR Screening Data. The table above represents cumulative data collected
from all PCR reactions during the course of this thesis. Strains are indicate in the first column by name. “Cag”
column refers to the presence of absence of the cagPAI as determined by the positive amplification of either
cagA or cagY genes. “Phage” column refers to the positive amplification of at least three prophage genes or
open reading frames. “+” signs indicate that a product was amplified for a specific strain and primer set.
signs indicate the lack o f an amplicon from a specific strain and primer set. “(+/-)” indicates ambiguous result.
Blank cells indicate a PCR reaction has not yet been performed for a given strain and primer set. The majority
of data regarding gene p7 were obtained from Lauren O ’Hagan.
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Figure S2. Basic Schematics of Original pBluescript and pUC4K. The above schematics depict the major
characteristics of the original pBluescript and pUC4K vectors utilized for this thesis. Resistance and LacZ genes
are color-coded and labeled. Dotted lines indicate non-coding vector sequence. Black lines indicate location of
multiple cloning sites. Restriction enzyme cutting sites are listed by order of appearance on the vector; specific
base-pair locations are provided for each cut site for pUC4K
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pKAL2 Sequence Confirmation
KA L.Rev.3

K A L.Fw d.3

GGGGGTTAATAAGOCTCAATCGGTAAATTiTTATTTTGlATCCTlICTGTXiAnTT
GTATCAAAACACGATmAGAAf^CAATCTTACTATCCATGCAGGGVGTGTGAr
TGGAGGCGATGGCTTTGGTTATGCACACAGCGCTnAGGAGAGCATGAATTCCC
OGGATCCGTCGACCTGCAGGGGGW&GGGGGAAAGCCACGTTCTGTCTCAAAATC
TCTUATGTTACATTGLACAALATAAAAATATAIXATCATGAAGAATAAAACrGTC
TCCTTAGATAAACACTAATACAAGGGGTGTTArCAGCr'.ATATTCAACGGGAAAC
RMKMKa CTCrrCCTCGAGCOCCCGATTAAATTO-AACATGGATGCTGATTTATATGGGTAT
Gtne
AAATGGGCTCGiOGATAATCT'CGGGCAATCAGGTGCGACAATCTATCGATTGTAT
GGGAAGCCCGATGCGGCAGAGTTGTTTC l GAAACATGGCAAAGTAGCGTT GCCA
ATCATXnTACAGATGACATGGTCAGACTAAACTGGCTGACGGAATrrATCCCTC
m itJU U GATtAAGCA I rHATtXGTArraTGAT

GCAATT1C T TCA G CA TA A G A G CG TCTG 'IA TA C CA A TC TTTn'A CCA CTTC TC TT

(A«K

l* * 0

C U A T C I C T T C C A I M C G G C ATAAAI .A I.A A u T T T rT A A l 7 U . l < J U J U .A TI A 1
A A A A t I X 'tm A M A A 4 T A A A C T C 7 t:a A T W J ^ M T r T a A T T r r r t M n T M :
a .T C A A IA A T C rA A T CT A A A A lX G C A tCCC TG A T T T CA T CA G CCA T T T TA T CA
CC A TuO X G CA A TTC CCC CiC A TC CG TCCA C CTG CA CiG CG G CC G C G G C CG rrG
AGCTCTGCCTCGTGAAGAAGGTGTFGCTGACTCATACCAGGCCTGAXrCGCCC
CATCATCCAGCCAGAAAjG TGAGGGAGCCACGGTTGATCACAGCTTTGTTCTA

K*n

G G TG C A C C A C T T G C T G A T T T T G A A C TrT T G C T T T G C C A C G G A A C G G T tT G C G

R u n t i m e TTCTCG G G AA GATGCGTGATCTGATCCTTCAACTCAGCAAAAGTTCGATTTAT

C *r*

rr.A A C A A M X C G C C tnT X lX T r.A A C T G A G C U T A A T G C T irrG C r.A G 'T C T T A C A A
CO U tTrA A G CA A TTLTC A A TTA G A A A A A C TCA rcG A U C A TG A A A TG A A A A CT
G C A A T T T A T T C A T A TC A C G A T T A T C A T A C C A T A T rm C A A A A A C C C C T T T T C
rCTAArCAAGCACAAAACTCACCGAGGCACTTCCATAiCCATGGGAAGATTCC
GCGATCGCTCTGCGATTCGAATOGTCAA

904 bp region
upKrcam of
prophage

Kanamycin Resistance Gene

L acZ //£t
/[

£JS%\LacZ
pKAL2

T o ta l te n g ttc

T3

7 7 8 b p r e g io n

downstream of
prophage

Ampicillm Resistance Gene

GATGAATCAAGCGGTGGt CCCOGCI CTAGACTACTGGATXXGCCTAT7CACAT
AAACAGACAtXGGCTCTATCACCCCAATGGCATAAGCAAGCTGCACGGTCCCT
TTimXCAAAmXACTCGCTACCAAATTTTTAGCCMJtrACGGCCCCGCATA
AGCCCCGCTOCTATCGACTrTACTAGlCGTCTTTCIXCCrAAACCCTCOCOCCCC

p ..

S .B O O b p

T7
GGTCCTTG GCCCG TC& GA TG G ATG A TCA TG CTCCrTTA AG A A AA A TCTG A GTT
TA G A A G A A C T G G G C A A T G C C & G G A T O T A iriW . I T ItC A & C TT G T C T A C T G G

GirriUCTGaiGAAGTtA^TTTTCnXATUrrGGCTA'n.ATGTTATMAjCAn;
G W .G I T C n.,G A U .A A A A A i:A 'rA A T A A A i.< 7A t G i 7 A n v m . G A T T T « ATA

A17XGCCCAACT<X£CCCATAAtlATC£ACCATCATTTTTCT6CCCGTCAAGt

A A G A A I^A T A A G G G G T A tT G A T C A A A IT A A G iC eA A rrG T T A A G C G G C lA T T t;

ICGCArCGCCrTGCCCCCCACCAATAACCAAmTCCTCTACCATrGAGAAAA
AACTTGATATTGrCATGCAAATATTCnTGGCTAAAACCTTATACACGATCTC
TTCAATCACGGCrTCTTTTAAATCTTTTTGCGAAACnCTGGGGiAATGTT&G
GTGGAAACGACAATCGTATCAATGCTTACAGGCTIG n GTITICATAACGCAC
GCTCACTTGAGACTTGCCATCAGGCCTTAAAAAA&GCAGACTGTTGTTTTTT

T A T T G A A A tC C A A T T T T tA A A C iiA m T G A A C T C C A T G C T T T A C iC X fA A T T C
GATAAGGCCACGCCTAATGATATTAGCTATATTGACCAAGCGCGCTACCTTAA
ACTTTTAAAAGATTCAAAAGCCGGGGCGCT CTTTATOCGTAAAAAACAAT C l

TXrTAAAGTGCGAAAACACATGCAAGCnTAATCCTGGATAACCCGCATCTAGC
C T T T GCTAAAGCTTCGCATGC CTTTAAAATCG C 1 1 im iA A A A A C C C A G A A

TCnTITTGAGC&AGAGCUAAAGTGAGLTGGTGGCrrAAATGAATCGGTAAA

AGCCTGAATCAGCCTAAACArrrTAAAAAACTAALGATtATGCCtXATGmt

GGGCATGAtiOZITTCAGTCnXTTGLACGCAtAAQCCAAACAXAAGOiXTTUA
TtXCCCGCCCCAATCrCGCCATCTTCTCTATCCACCCCTTGATTAATTAT'CAGG

AATrGCGAGAGCGAjrTAGAAATrCGCCAAAACTLTTTGATTTATCCOGCGCC
TG G T G A T C G C T U A TG G G G TC A A A A T C G G C lA A A A A T T C T A rnT T G T T A TC C T

crrnGcrcGcccAATGCtAArrrA

CGTCTGA TTTTTCriTA TG AA A A CA iCCG ATtA

Figure S3. Sequencing Data from Four Separate Reactions Confirming Proper pKAL2 Construction. The
center of this figure depicts vector pKAL2 in schematic form. Sequence generated from four separate Big Dye
reactions (via Sanger sequencing), using primers T7, T3, KAL.Fwd.3, and KAL.Rev.3, are displayed. Sequence
is color-coded to indicate corresponding location on vector. Sequence indicates the proper insertion and
orientation of the MetK and LpxD amplicons, as well as the Kanamycin resistance gene sourced from digested
pUC4K plasmid DNA.
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Appendix A: Forsyth Lab Genomic DNA Extraction Protocol
1. Streak one full plate of H. pylori for each chromosomal prep and allow to grow for 24-36
hours
2. Harvest cells with a sterile cotton tipped swab and put into 1 mL of sterile 0.9% NaCl
(saline)
3. Pellet cells by spinning for 5 minutes at 6,000 rpm in the microcentrifuge and pour off
supernatant
4. Resuspend cells in 560 ul of TE pH 8.0 or Elution Buffer
5. Add 30 uL 10% SDS and invert to mix
6. Incubate at 37 degrees Celsius for 30 minutes
7. Add 100 ul 5M NaCl and invert to mix
8. Add TOO- ul 10% CTAB/0.7M NaCl (preheated to 65 degrees Celsius) and invert to mix
9. Incubate for 10 minutes at 65 degrees Celsius
10. Add 700 ul chloroform and invert to mix
11. Centrifuge for 5 minutes at 10,000 rpm in microcentrifuge
12. Remove aqueous, top layer and put into a new tube
13. Add 700 ul phenol:chloroform:isoamyl alcohol and invert to mix
14. Centrifuge for 5 minutes at 10,000 rpm in microcentrifuge
15. Remove aqueous, top layer and put into a new tube
16. Add 700 ul chloroform and invert ot mix
17. Centrifuge for 5 minutes at 10,000 rpm in microcentrifuge
18. Remove aqueous, top layer and put into a new tube.
19. Add 600 ul isopropanol and invert until DNA appears
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20. Centrifuge for 10 mintues at 10,000 rpm in microcentrifuge
21. Remove supernatant and allow pellet to air dry
22. Resuspend pellet in 100 ul lOmM Trist, pH 8.5 or Elution Buffer or TE pH 8.0
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Appendix B l: PCR Primer Sequences and Melt Temperatures
G ene/Junction

Primers

Primer S e a u e n c e 5'->3'

I n te g r a se

1 1 1 l.r e v .l

TGTGCCGTGTGGTGTAAAGC

~S/'ze = 600bp

o r f3 .fw d .l

CGCCGAAAAACAAACGCAAAGGATAC

T m X lQ
62
6 4 .4

Gene/Junction

Primers

Primer S e a u e n c e 5'->3'

orf6

J68 o r f6 .r e v .l

GATACAAGCCACTAAATCGCATCC

6 0 .5

~S /'ze = 500bp

J68 o r f6 .fw d .l

CGAAAAACAAGCCCAAAAACCAGC

6 1 .6

G ene/Junction

Primers

Primer S e a u e n c e 5'->3'

H P 0453

H P 453.rev. 1

GGCGTGCAAGTGTGTTTGGAAGTG

~S /'ze = 250bp

H P 4 5 3 .fw d .2

CTAACTCTTCAAGCGTGTAATGTG

n

H
3
0

Tm ( ° C )

64
5 9 .6

G ene/Junction

Primers

Primer S ea u en ce 5'->3'

H P 4 5 3 x o r f2

o r f2 .r ev .5

G CTTGTTTCTGTCT CATTTCTCTGTCTC

6 3 .8

~ S /z e = 550bp

H P 4 5 3 .fw d .2

CTAACTCTTCAAGCGTGTAATGTG

5 9 .6

Tm f ° C )

G ene/Junction

Primers

Primer S e a u e n c e 5'->3'

Tm f ° C )

H P 0 4 5 3 x o r f2 (2 )

J 6 8 .o r f2 .r e v .4

TTGCTTTAGGCGTTAGCGGG
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~ S /z e = 550bp

H P 4 5 3 .fw d .l

CACTTCCAAACACACTTGCACGCC

64

G ene/Junction

Primers

Primer S e a u e n c e 5'->3'

orf6 (2 )

orf6R ev.2

GCCACTAAATCGCATCCTTGC

~ S /z e = 550bp

orf6F w d .2

GAGAACGAAAAAACGACGGAC

G ene/Junction

Primers

Primer S e a u e n c e 5'->3'

P7

LKO Rev. 2

GTCAAATCATCTGGCGTTGTCATCA

6 1 .8

~ S /z e = 700bp

LKO F w d .l

TGAAGTCTCGTATTCTCTAACCCCAAC

6 2 .4

Gene/Junction

Primers

Primer S e a u e n c e 5'->3'

M81

M81 PCR Rev

GIAAGAGI ICI 1 1 IAIAAGCICGI IGIGAICG

6 5 .4

~ S /z e = 550bp

m 8 1 g s p l ups

CACCTAAACCAATGCGAAAGGTCAGCGTTTGAAG

7 0 .5

Tm ( ° C )
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5 9 .2

Tm ( ° C )

Tm ( ° C )

Gene/Junction

Primers

Primer S e a u e n c e 5 ’->3'

Tm f °C )

o r f ll

(D F S ) o r f llF w d .l

CCI 1 1 IAGGKAIAGAAAGCG

4 9 .2

~ S iz e = 2 0 0 b p

( D F S ) o r f llR e v .l

CTAAAAGRYTRCAYAAAACGC

5 0 .2

G ene/Junction

Primers

Primer S e a u e n c e 5'->3'

o r f l3

(D F S )o r fl3 F w d . 1

GATAAAGGCATGCTSTATAGC

5 3 .5

~ S iz e = 2 0 0 b p

(D F S )o r fl3 R e v . 1

CCGATCAARCAACCGATCGAG

57

Tm r a

G ene/Junction

Primers

Primer S e a u e n c e 5'->3'

o r f l7

(D F S )o r fl7 F w d .l

AACATGCCTCCAAGCTATGG

5 5 .2

~ S iz e = 150bp

(D F S )o r fl7 R e v . 1

GGTTAGCGATCTTTCTGC

5 0 .7

Tm ( ° C )

Gene/Junction

Primers

Primer S e a u e n c e 5'->3'

orf23

(D F S )o r f2 3 F w d .l

AGCGATACGAGTTGCACGGT

5 9 .1

~ S iz e = 1 7 0 b p

(D F S )orf23R ev. 1

CATYTCTTCATC RTGTTG C

4 9 .2
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Tm ( ° C )

G ene/Junction

Primers

Primer S eq u en ce 5'->3'

LpxD

L pxd F w d.l

TTTTCAAACGATTTTGAAGTGCATGC

5 5 .8

~ S /z e = 870bp

L pxD R ev.l

CATGGATTTCCATAGCAGGGATCG

5 7 .6

Gene/Junction

Primers

Primer S e a u e n c e 5'->3'

MetK

M etK Fw d.l

GCATGATCACTGGCGAGTTAAAAAC

5 9 .8

~ S /z e = 720bp

M etKRev.2

TCGCAAACCCCACTCGCTACCA

6 3 .2

Gene/Junction

Primers

Primer S e a u e n c e 5'->3'

L p x d x M e tK

LpxD Fw d.2

CGATCCCTGCTATGGAAATCCATG

5 7 .6

~ S iz e = 350b p

M etK R ev.l

CAGAAGI 1 1 1 IAACTCGCCAGTGATC

5 9 .8

Gene/Junction

Primers

Primer S e a u e n c e 5'->3'

G lu co k in a se

glckin.F w d

IG G C IC II 1 IGCIGIGGCIACG

~ S iz e - 1 5 0 b p

g lck in .R ev

CGCTAATGGCATAGGCTTGC
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Gene/Junction

Primers

Primer S e a u e n c e 5'->3'

Tm ( ° C )

O rientation

KAL.Rev.3

ACTCTTTGATTTATCCGGGCG

5 5 .1

KAL.Fwd.3

CTCGCCAATGCCATTTAAAACCGC

5 9 .7

G ene/Junction

Primers

Primer S e a u e n c e 5'->3'

D o w n str e a m

KAL.Fwd.2

CCCCG AATTC ATG CTCTCCTA AAG CG GTGTGTG C

6 7 .2

~ S iz e = 780b p

KAL.Rev.2

CCCCCTCGAGAAAATGGAATGAAATCAATGCTCC

6 3 .3

G ene/Junction

Primers

Primer S e a u e n c e 5'->3'

U p stream

K AL.Fwd.l

CCCCGGATCCGCGTATTCACATAAACAGACACCG

6 6 .6

~ S iz e = 9 0 0 b p

K AL.Rev.l

CCCCGAAATTCCGGGCATCCTGATAAAATGGCTG

6 6 .3

64

I m ( °C)

Tm r o

Tm.C.C)

Tm (°_C)
6 3 .8

Tm ( ° C )

Tm ( ° C )

Appendix B2: PCR Thermal Cycler Settings by Primer Set
Cvcler Settings

Gene/Junction

Primers

In te g r a se

1 1 1 l.r e v .l

T e m p (°C )

94

59

72

~ S /z e = 600bp

o r f 3 .f w d .l

T im e (m in :s e c )

:3 0

:30

1 :0 0

3 0 C ycles
72
7 :0 0

i
Gene/Junction

Primers

orf6

J68 o r f6 .r e v .l

Cvcler Settinqs
T e m p (°C )

94

57

72

72

- S iz e = 500bp

J68 o r f6 .fw d .l

T im e (m in :s e c )

:3 0

:3 0

1 :0 0

1 0 :0 0

72

Cvcler Settinas

3 0 C ycles

Gene/Junction

Primers

H P 0453

H P 453.rev. 1

T em p (°C )

94

57

72

- S iz e = 250bp

H P 4 5 3 .fw d .2

T im e (m in :s e c )

:3 0

:3 0

:45

3 0 C ycles

1 0 :0 0

1
G ene/Junction

Primers

H P 4 5 3 > < o rf2

o r f2 .r e v .5

- S iz e - 550bp

H P 4 5 3 .fw d .2

G ene/Junction

Primers

H P 0 4 5 3 > < o r f2 (2 )

J 6 8 .o r f2 .r e v .4

- S iz e = 550bp

H P 453.fw d . 1

Cvcler Settinqs

3 0 C ycles

T e m p (°C )

94

55

72

72

T im e (m ir n se c )

:3 0

:30

1 :0 0

1 0 :0 0

Cvcler Settinqs

3 0 C ycles

T e m p (°C )

94

59

72

72

T im e (m ir n se c )

:3 0

:30

:45

1 0 :0 0

G ene/Junction

Primers

orf6 (2 )

orf6R ev.2

Cvcler Settinqs
T e m p (°C )

94

57

72

72

~ S ize = 550bp

o rf6F w d .2

T im e (m ir n se c )

:3 0

:3 0

:45

1 0 :0 0

G ene/Junction

Primers

3 0 C ycles

i
Cvcler Settinqs

3 0 c y c le s

p7

LKO Rev. 2

T e m p (°C )

94

55

72

72

~ S ize = 700bp

LKO F w d .l

T im e (m ir n se c )

: 30

:3 0

1 :0 0

7 :0 0

Gene/Junction

Primers

M81

M81 PCR Rev

- S iz e = 550bp

m 8 1 g s p l ups

Cvcler Settinqs

i

3 0 c y c le s

T e m p (°C )

94

61

72

72

T im e (m ir n se c )

:3 0

:3 0

1 :0 0

7 :0 0

Gene/Junction

Primers

o r fll

( D F S ) o r f llF w d .l

T e m p (°C )

94

53

72

72

~ S iz e - 2 0 0 b p

( D F S ) o r f llR e v .l

T im e (m ir n se c )

:3 0

:3 0

1 :0 0

7 :0 0

Cvcler Settinqs

3 0 c y c le s

Gene/Junction

Primers

o r f l3

(D F S )o r fl3 F w d .l

T em p (°C )

94

53

72

72

~ S iz e = 2 0 0 b p

(D F S )o r fl3 R e v .l

T im e (m in :s e c )

:30

:3 0

1 :0 0

7 :0 0

Cvcler Settinqs

Cvcler Settinqs

3 0 c y c le s

G ene/Junction

Primers

o r f l7

(D F S )o r fl7 F w d .l

T e m p (°C )

94

53

72

72

~ S iz e = 1 5 0 b p

(D F S )o r fl7 R e v .l

T im e (m ir n se c )

:3 0

:3 0

1 :0 0

7 :0 0

Cvcler Settinqs

3 0 c y c le s

G ene/Junction

Primers

orf23

(D F S )o r f2 3 F w d .l

T e m p (°C )

94

53

72

72

~ S iz e = 1 7 0 b p

(D F S )o r f2 3 R e v .l

T im e (m in :s e c )

:30

:3 0

1 :0 0

7 :0 0
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3 0 c y c le s

i
Gene/Junction

Primers

LpxD

L pxd F w d.l

T em p (°C )

94

61

72

|

72

~ S /z e = 870bp

L pxD R ev.l

T im e (m in :s e c )

:3 0

:3 0

1 :0 0

'

7 :0 0

Cvcler Settinas

i

3 0 c y c le s

i
i
i

G ene/Junction

Primers

MetK

M etK Fw d.l

T em p (°C )

94

61

72

|

72

~S /'ze = 720bp

MetK Rev. 2

T im e (m ir n se c )

:3 0

:3 0

1 :0 0

7 :0 0

G ene/Junction

Primers

L p x d x M e tK

L pxD Fw d.2

~ S iz e = 3 5 0 b p

M etK R ev.l

7 :0 0

G ene/Junction

Primers

Cvcler Settinas

3 0 c y c le s

T em p (°C )

94

61

72

'
i
i
i
i
'

T im e (m ir n se c )

:30

:3 0

1 :0 0

i

Cvcler Settinas

Cvcler Settinas

3 0 c y c le s

72

i

3 0 c y c le s

G lu co k in a se

glck in .F w d

T em p (°C )

94

58

72

i

72

~ S iz e = 1 5 0 b p

glck in .R ev

T im e (m ir n se c )

:3 0

:3 0

1 :0 0

!

7 :0 0

G ene/Junction

Primers

O rientation

KAL.Rev.3

T e m p (°C )

94

52

72

,

72

KAL.Fwd.3

T im e (m ir n se c )

:30

:3 0

1 :0 0

'
i
i
i

7 :0 0

1

G ene/Junction

Primers

Cvcler Settinas

Cvcler Settinas

i

3 0 c y c le s

3 0 c y c le s

D o w n strea m

KAL.Fwd.2

T e m p (°C )

94

60

72

|

72

~ S iz e = 7 8 0 b p

KAL.Rev.2

T im e (m ir n se c )

:30

:3 0

1 :0 0

1

7 :0 0

G ene/Junction

Primers

U p stream

K AL.Fwd.l

T em p (°C )

94

61

~ S iz e = 9 0 0 b p

K AL.Rev.l

T im e (m ir n se c )

:3 0

:3 0

:

Cvcler Settinas

66

72

i
i
1

72

1 :0 0

i

7 :0 0

3 0 c y c le s

Appendix C: H. pylori Single-Strain UV Induction Protocol
Equipment Required:
-Three blood agar plates with sufficient growth of H. pylori strain
-50mL of “Broth Stock” (45mL SFBB/lOmM MgS04/10mM CaC12, 5mL FBS or NCS, and
50ul Vancomycin (lOOOx))
-Spectrolinker X L -1500 UV Crosslinker
-3 sterile swabs
-3 sterile, metal-capped, 16x150mm glass tubes
-6 15mL Falcon tubes
-3 50mL Falcon tubes
-4 spectrophotometer cuvettes
-15 Eppendorf (microcentrifuge) tubes
-3 sterile lOmL syringes
-3 18G 1 Vi sterile needles
-3 0.22 micron filters
Pre-Induction Notes:
- Sterilize and prepare media prior to beginning protocol
- Ensure that the necessary amount of sterile glass tubes are available
- If possible, label all Eppendorf, Falcon, and glass tubes ahead of time
- Incubate desired strain on a single blood agar plate until growth is sufficient for passing to
three separate BAP’s (Blood Agar Plate, henceforth abbreviated as such). After all three
plates have grown for 24-48 hours, follow the protocol below:
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Induction Protocol:
1- Combine 45mL of SFBB/lOmM MgSO4/10mM CaC12, 5mL FBS or NCS, and 50pL
Vancomycin (lOOOx) in a 50mLFlacon tube. Label tube “Broth Stock.” (If more than 50mL
of broth is necessary, use the same proportions of ingredients)
2- Randomly label each of the three blood agar plates “Control”, “X I”, “X2”, and place back
in C02 incubator until ready for use.
3- Acquire “Spectrolinker X L -1500 UV Crosslinker” from teaching lab. DO NOT REMOVE
HELICOBACTER PYLORI PLATES FROM THE FORSYTH LAB.
4- Irradiate each blood agar plate according to its designation. The control plate receives no
irradiation. For experimental plates, plate “X I” will receive 1.5 mJ/cm2, and plate “X2” will
receive 2.5 mJ/cm2. To operate Spectrolinker and irradiate each plate, follow these steps:
-Turn power ON
-Press “ENERGY” button
-Input appropriate mJ/cm2 dosage using numeric keypad. Since the unit
measures UV radiation in “X I00 microJoules/cm2”, convert accordingly. For
example, to administer a dose of 1.5mJ/cm2, input the number 15 into the unit
(15 x 100 microJoules/cm2 = 1.5 mJ/cm2).
-Place plate agar side up in Crosslinker and remove lid. CLOSE DOOR.
-Press “START” (Irradiation will begin, lasting approximately 0.5 - 2
seconds)
-Replace lid and remove plate from UV Crosslinker
-Turn power OFF
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5- Once all samples have been appropriately irradiated, return Crosslinker to teaching lab and
proceed to next step.
6- Using sterile swabs, pass the bacteria from all three plates into labeled, sterile, metalcapped, 16x150mm, glass tubes, each containing 7mL of the aforementioned “Broth Stock.”
7- Determine concentration of newly created cell suspensions via spectrometry using
dilutions:
BLANK

-Pipette 500 pL of pure broth stock into empty cuvette

1:10

-Pipette 450 pL of broth and 50 pL of irradiated sample into empty cuvette

8- Calculate and record the average non-diluted suspension concentration values for each of
the four experimental groups (Control, X I, etc.)
9- Place all three labeled glass tubes in the rotating rack located in the upper incubator.
Check that rotation speed is approximately 60%, temperature is 37.0 C, and that C02 levels
are adequate (BB is at approximately 80 on the incubator’s gauge). Check C02 tank levels as
well, ensuring that the right-hand gauge does not read less than 200 psi. Incubate samples for
36 hours, taking aliquots at time points specified below.

10- After 30 minutes of incubation, remove lm L from each sample, pipette aliquot into a
respectively labeled eppendorf (microcentrifuge) tube, and freeze at -80 degrees C.
11- After 1 hour of incubation, remove lm L from each sample, pipette aliquot into a
respectively labeled eppendorf (microcentrifuge) tube, and freeze at -80 degrees C.
12- After 36 hours of incubation, check that rotation speed is still approximately 60%,
temperature is 37.0 C, and that C02 levels are adequate (BB is at approximately 80 on the
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incubator’s gauge). Check C02 tank levels as well, ensuring that the right-hand gauge does
not read less than 2 0 0 psi. Remove lm L from each sample, pipette aliquot into a respectively
labeled eppendorf (microcentrifuge) tube, and freeze at -80 degrees C.
13- Determine concentration of remaining suspension for each sample as conducted in steps
7 and 8.
14- Remove samples from incubator and use sterile pipettes to transfer the remaining
contents of each tube to respectively labeled 15 mL falcon tubes.
13- Centrifuge samples on “Program #1” (10 minutes, 20 degrees C, 4360 RPM)
14- Using sterile pipettes, transfer the supernatants from the sample tubes to respectively
labeled 50mL falcon tubes
15- Using sterile lOmL syringes, 18G 1 V2 needles, and 0.22 micron filters, filter each of the
samples into labeled 15mL falcon tubes.
16- Take two, 1.5mL aliquots from the filtered supernatant of each sample and place in
labeled eppendorf (microcentrifuge) tubes. Freeze aliquots at -80 degrees C.
17- Refrigerate (+4 degrees C) remaining ~3 mLs of each sample’s filtered supernatant or
proceed directly to RNA extraction for use in RT-PCR. Sample will remain stable for
approximately 1 week at +4 degrees C. After 1 week, sample should be discarded.
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Appendix D: Preparation of Fluorescentlv Stained Virus Samples for Enumeration by
Epifluorescence Microscopoy
PPE:
Safety glasses

Gloves

Equipment:
Vacuum manifold
1000 pi pipettman
200 pi pipettman
10 pi pipettman
Timer
Anodisc filters
Supor filters
GFF filters
Fine point forceps
Immersion oil
Ice bucket and ice
Filter-sterilized Milli-Q water
Glass slides
Round glass coverslips
Antifade solution
1000X SYBR Gold stain
Eppendorf tubes
Kimwipes
Glass plate
Heavy book (OPTIONAL)
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NOTES:
- Keep tubes of 0.22-um filtered sterile Milli-Q water on hand for dilutions.
- Stains (and some samples) are light sensitive. Work in as low light as possible and keep tubes covered
with foil when not in use.
- SYBR Gold comes from the mfr at 10,000X - make a 1000X working stock for slide-making as
needed.
- In order to ensure coverage of Anodisc filters, load at least 400 ul of sample onto each filter. If
smaller volumes or dilutions are needed, make up in 1-ml volumes. EX: 50 ul sample in 950 ul sterile
Milli-Q water.
If the samples to be enumerated are frozen, start at step one. If samples are not frozen, start at step 2.
1. Turn on water bath to 36°C or collect ~20mL warm tap water in a beaker. Thaw samples in
water bath or warm water.
2. Place thawed/liquid samples on ice. Thaw 1000X SYBR Gold, then place on ice. Keep all
samples, stains and antifade solution on ice during the procedure.
3. If necessary, prepare dilutions of your samples ahead of time in Eppendorf tubes.
a. Keep diluted samples on ice, and do not dilute until just before slide prep.
b. Dilutions should be made in 0.2mm syringe filtered Milli-Q water, SM, or another
appropriate solution.
4. Lay out glass slides with frosted writing edges. Each slide can hold 2 Anodisc filters. Label the
slides with experiment and sample name(s) and volume on each filter. Use arrows to indicate
which sample is on the left and right sides of the slide
5. Example:
GOS
Station 3
VC 500ul <Station 4
VC 500ul ->
6. Prepare 2.5X SYBR gold from 100X stock: you will need 400 ul of 2.5X SYBR for each
Anodisc filter. To stain TWO Anodiscs, add 2 j l l 1 SYBR Gold to 798 j l l 1 filtered Milli Q water in
an Eppendorf tube. Vortex to mix thoroughly.
7. Wet frits (mesh screens) of the manifold with Milli Q water.
a. Using forceps, place a glass fiber filter (GF/F) on the frits and wet with Milli-Q.
b. Place a 0.22 um Supor filter on top of the glass fiber filter and wet as before.
c. Place an Anodisc filter on top.
d. Carefully place tower on top and clamp to the manifold.
8. Make sure all unused ports are closed.
9. Turn on vacuum to remove any water and anneal filters together, 5-10 seconds.
10. Turn off the vacuum and open an unused port to vent.
11. Load the specific volume necessary for your sample.
(Note. When in doubt as to the volume of sample needed, make 1-2, filters of various loading
concentrations and check counts under microscope before proceeding.)
12. Close off all unused ports.
13. Turn on vacuum, making sure ports containing samples are open. Leave vacuum on until filters
appear dry, usu. 1-2 min.
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14. Close off all ports and turn off vacuum.
15. Open an unused port and allow vacuum to dissipate completely. Close ports containing
samples.
16. Add 400 jLil of 2.5X SYBR Gold to each filter and cover the manifold with aluminum foil to
block out light.
17. Stain under cover for 15 min.
18. While samples are staining, prepare previously labeled glass slides by adding a drop of
immersion oil OR 10 j l l I of Antifade where the filters will be mounted. Set out one round coverslip for each sample and place a drop (20 pi) of Antifade solution in the center of each. Place
cover-slips on an Eppendorf tube rack so that they can be easily picked up with forceps.
19. After 15 minutes, close vent ports, turn on vacuum and open sample ports.Drain off stain until
filters are dry (1-3 min). Leave vacuum on.
20. With vacuum still on, unclamp and remove filter tower. Use forceps to carefully lift off
Anodisc filters, leaving the other filters on the manifold. Dry filters by:
a. gently waving it in the air (keep a firm grip with forceps)
b. OR applying a gentle stream of air to the back of the filter using the in-house air system.
21. Place filter on the drop of oil/anifade on the prepared glass slide.
22. Place coverslip with Antifade, drop-side down, onto the filters.
23. Cover slides with a Kim-wipe. OPTIONAL: Place the glass plate over top of the slides, and
top with a heavy book (e.g., Fisher catalogue). Press slides for -3 0 sec. This step tends to
reduce air bubbles in between the cover-slips and filters.
24. Immediately put pressed slides into a slide box or wrap in A1 foil.
a. Store slides in -20°C freezer up to 1 month.
b. Fluorescence will fade over time, so the sooner slides can be viewed, the better.Usually
photographing within 2 days gives the best results.
25. Once all samples have been processed, clean up.
a. Place all waste (tubes, support filters, etc.) into Biohazard container.
b. Rinse and drain the manifold with Milli Q water, dry off all metal parts.
c. Rinse towers with Milli-Q and dry with Kimwipes.
d. Leave ports open to ventilate.
e. Put all other items back in their proper locations: SYBR Gold and antifade, -20C
freezer; samples - refrigerated or frozen.
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Appendix E: TEM Grid Preparation
Material Prep:
I - Cut wedges from filter paper
2- Acquire PBS/Buffer/H20 , Uranyl Acetate, experimental samples, plastic petri dishes, scotch
tape/pelco tabs, grids, pipettes and tips
Protocol (for a single grid):
1- Stabilize grid in lid of petri dish by securing edge of grid (shiny side up) with tape/pelco tab to
the surface of lid
2- Pipette 5 microliters of sample on to grid
3- Wait 5 minutes
4- Wick away liquid with filter paper wedge
5- Pipette 5 microliters of PBS/Buffer/H20 on to grid
6- Wait one minute
7- Wick away liquid with filter paper wedge
8- Pipette 5 microliters of PBS/Buffer/H20 on to grid
9- Wait one minute
10-Wick away liquid with filter paper wedge
II - Pipette 5 microliters of uranyl acetate on to grid
12- Wait one minute
13- Wick away liquid
14- Seal petri dish with parafilm and label appropriately
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Appendix F: TEM Basic Operation Checklist
Initial Status Check
-Ensure stage drive is powered ON
-Power key for scope should be in position 1
-Open V3 indicator light should be green
-no other indicator lights should be illuminated
-Chiller unit (located behind scope) should read 21 degrees C
Grid Loading
1- Key to position II
2- Open V3 - confirm that scope is operational (no error indicators). Green “Beam” button
(left-hand panel) should illuminate).
3- Pull specimen loader back (towards you) until it stops, then turn counter-clockwise to 1:00
until it stops, then pull back toward you again, until stop.
4- Turn the airlock (large knurled wheel) counter-clockwise to access specimen loader.
5- Insert and screw in the tool for removing and handling the specimen loader.
6- Remove the specimen loader using the tool, and place the specimen loader horizontally in
stand, face up
7- Place the cap tool on the specimen loader cap, and use the tool to fold the specimen loader
up, locking in position with metal arm.
8- Slide down the friction collar on the cap tool.
9- Unscrew specimen loader cap and set aside
10- If there is a grid present, carefully remove and place in well-labeled container
11 - Place desired grid carefully into small cup/groove
12- Using the cap tool, carefully screw cap back on approximately 1.25 turns to cover grid. DO
NOT OVERTIGHTEN or STRIP THREADS.
13- Using cap tool, unfold the specimen loader back to horizontal position
14- Pick up the specimen loader using the handle tool and GENTLY shake to ensure that grid
cap is secure
15- Carefully insert specimen loader (with grid) into the airlock.
16- Unscrew handle tool; after removal, tap the specimen loader gently to ensure full insertion
17- Turn the airlock (large knurled wheel) clockwise to seal in the grid unit. Confirm turned all
the wav!
18- Press “PUMP” button (green button, left-hand panel) and then insert the specimen loader
into the column: press red button on the slider and turn to 3 o ’clock position
19-WAIT: Confirm that “LOCK IN” button is no longer illuminated
20- Once vacuum is achieved, move grid slider to position one
21- Green button for “BEAM” should be illuminated; press “BEAM” button
2 2 -Press “FILAMENT” button (toggle).
23- Align beam, then reduce brightness before loading grid.
24- Move grid slider to position 2 and then to position 3 (grid is now inserted into beam)
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Operation
Brightness & Magnification
-Brightness must generally be increased with each increase in magnification
-Avoid turning brightness knob to the left for dimming. Always dim beam by turning
brightness knob clockwise.
-30K to 50k magnification is preferred for phage particle “scouting”
-If beam is not centered at magnification, adjust with “Beam Alignment” on the right-hand
panel.
Focus
-Course and fine focus knobs are utilized
-To maximize clarity, use ocular and slide down plate
Navigation
-Travel in the same direction to avoid covering the same area twice
-Avoid hitting “zero” on either coordinate axis
-Navigate with trackball and/or x and y +/- directional buttons
Software
Open XCap software for pictures
Click “Trig” tab
-single shot
-camera mode (controlled)
Imaging
-Lever to bring down camera is located directly behind V3 lever on right of scope (be careful!)
-Once in position, click “SNAP”, then File -> Save image -> Folder -> Filename
-When saving image on computer, be sure to indicate magnification

Basic Shutdown
1- Leave grid in specimen holder
2- Pull slider on specimen holder all the way straight pack (towards you) (position 1)
3- Set magnification to 3,000X and intensity to low so beam is barely visible
4- Press “FILAMENT” (beam off)
5- Press RED button to right of FILAMENT (energy off)
6- Wait for green button to illuminate to indicate beam is powered off
7- Close V3 (Green “Open V3” indicator light should come on).
8- Ensure power key is returned to position 1
9- Put lid on screen and petri dish over trackball
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Appendix G: HHMI Phage DNA Purification Protocol
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Part B. Isolate and Purify Phage Genomic DNA

Objective
T he p rim a ry ob jectiv e is to is o la te a n d p u rify p h a g e g e n o m ic DNA in su ffi
cien tly h ig h a m o u n ts fo r re s tric tio n a n a ly sis a n d se q u e n c in g p ro to co ls.

Sup plies
□
□
□
□
□
□
□
□
□
□
□

A s te rile se ro lo g ic a l p ip e tte (5-rnL)
Iso p ro p a n o l' (80% ) (2 mlVIO m L ly sate)
P iia g e p re c ip ita n t (4 mlVIO m L ly sate)
N u c le a se M ix (40 fiL /10 m L ly sa te )
P ro m c g a DNA C lean Up K it1'
1.5-m L n u c ro c c n trifu g c tu b e s (6)
A 15-m L c le a r sc rew -cap p ed tu b e (e.g.. O ak R id g e tu b e)
S y rin g e s. 3-m L o r 5-m L
S terile d d ll.,0 (0.5 inL /10 m L ly sa te )
TE p rc -w a rm e d to BO C
G loves (latex o r vinyl)

Equipm ent
O
□
□
□
□
□
□

A h ig h -sp e e d c e n trifu g e
A m icrooenL rifuge
8 0 C h e a tin g b lo ck o r w a te r b a th
3 T C w a te r b a th
A re f rig e r a to r (o r ice)
- S O C fre e ze r
A sp e c tro p h o to m e te r. N a n o d ro p , o r flu o ro m c te r (a n d ac c e sso rie s) fo r
DNA q u a n tific a tio n

Procedure
A.

D egrad e b a cteria l DNA th a t Is in 10 mL o f p h a g e lysate,*
1. T ra n s fe r 10 m L o f th e flltc r-stc rile d p h a g e ly sa te in to a O a k R id g e tu b e.
S to re th e re m a u u n g ly sa te a t 4 nC.
2. P u t o n gloves.
3. Add 4 0 fiL N u c le a se Mix, screw o n cap , a n d n u x g e n tly b u t th o ro u g h ly by
re p e a te d in v e rsio n s. D o not vortex!

O

I f your lysate has a
titer>lCP pfu/mL. you
can dilute it e.g.. 1:2
or 1:10 with sterile
phage buffer.

W h en h a n d lin g t h e N u c le a s e M ix , y o u m u s t w e a r g l o v e s a n d w o r k in
a h o o d t o a v o id c o n t a m in a t in g o t h e r s o l u t i o n s w it h t h e m ix . A fte r a d d in g
N u c le a s e M ix t o y o u r s a m p le , c e p t h e t u b e s a n d d is c a r d y o u r g lo v e s
b e f o r e r e tu r n in g t o y o u r w o r k a r e a . O t h e r w is e , t h e e n z y m e s c a n
c o n t a m in a t e all D N A -c o n te in in g s o lu t io n s a n d ru in y o u r s a m p le .

4. In c u b a te a t 3 T C fo r 30 m in u te s.
5. L e t s it u n d is tu rb e d a t ro o m te m p e ra tu re (RT) fo r 1 liour.
f a r t 1 D i s s e c t B. l
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Pfcrt B. laolmln and Pnrlfy P fia p f*«nomtr DMA

B. P r e c ip ita te ph a^ c p a r tic le s.
1 .P u t o n a fre sh p a ir of gloves.

Remove os much
phage precipitant
solution as possible
without disturbing
the phage pellet.
Failure, to do so will
interfere with or
clog the column and
significantly reduce
your DNA yield.

2. U sin g a 5-m L p ip e tte , a d d 4 .0 m L o f p h a g e p re c ip ita n t so lu tio n to th e
n u c le a se -tre a te d ly sate , a n d c a p th e Lube.
3. M ix g e n tly b u t th o ro u g lily by in v ersio n .
4 .In c u b a te 30 m in u te s o n ioe or, fo r m a x im u m yield, o v e rn ig h t a t 4 C.
5 .P lac e th e tu b e in a h ig h -sp e e d c e n trifu g e a n d sp in a t 1 0 ,0 0 0 x g for
2 0 m in u te s .
6 .D e c an i th e s u p e r n a ta n t b e in g c arefu l n o t to d is tu rb th e p ellet. D ram
ex c e ss liq u id fro m th e pellet by in v e rtin g fo r 2 to 3 m u iu te s o n a p a p e r
tow el. D isc ard th e p a p e r tow el a n d y o u r gloves.
C. R e -su sp c n d th e p h a g e p ellet.
1 .A dd 0 .5 m L o f s te rile d d H ;J0 to th e pellet.
2 .G en tly re -su sp e n d th e p ellet by p ip c ttm g u p a n d dow n.
3 Allow to sit a t ro o m te m p e ra tu re fo r 5 -1 0 m in u te s (no m o re tlia n 10 m in 
utes).
D. O b tain th e D N A -p u riflcation k it from you r in stru cto r.
E. U ncoat th e p h a ge g en o m ic DNA.
1. P u t o n a fre sh p a ir of gloves.

Why wouSdo'i you want to
let the resuspervded phage
pari e es sit to o long in
solution?

o

T he re sin c o n ta in s g u a n id in iu m th io c y a n a te , a c h e m ic a l
th a t d e n a tu r e s p ro te in s . Do n o t g e t it on y o u r sk in !

2. A dd 2 m L o f p rc -w a rm e d (3 7 'C) DNA C lean U p R esin.
3 .U n o o at th e p h a g e p a rtic le s by g e n tly p ip e ttm g up a n d d o w n . G en tly sw irl
to m ix.
F. I s o la te th e p h a g e g en o m ic DNA.
1. You w ill n e e d tw o c o lu m n s fo r tin s p ro c e d u re . A tta ch o n e c o lu m n
su p p lie d w ith th e k it to a sy rin g e . R ep eat w ith th e sec o n d c o lu m n .

Pushing the solution
through sometimes
requires a great deal
of elbow grease.

2. Apply 1.25 mL o f w atc r-rcain -p h ag e-g en o m ic-D N A so lu tio n to e a c h c o l
u m n u sin g a p ip e tte .
3 .U se th e sy rin g e p lu n g e r to p u sh tin s s o lu tio n th r o u g h th e oolunni.
4. W ash s a lts a n d p ro te in s off DNA. F o r each colu m n :

R * r U rW nXHnl B *
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cfcr DNA

a. R em ove th e co lu m n fro m th e sy rin g e .

b. Remove the plunger from the syringe.
c. Rc-attach the syringe to the column.
d. Add a m L o f 8 0 % iso p ro p a n o l to th e oolunm .
e. P u sh th e iso p ro p a n o l th r o u g h th e c o lu m n w ith th e p lu n g er.
5. D ry e a c h co lu m n :
a. R em ove th e c o lu m n .
b. C e n trifu g e th e o o lu n m fo r 5 m in u te s a t m a x im u m sp e e d to rem o v e
th e iso p ro p a n o l (do th is in a d e a n m ic ro c e n trifu g e tu b e th a t h a s tiad
its lid rem oved).
c. T ra n s fe r th e c o lu m n to a clean , lid lc ss m ic ro o c n trifu g e tu b e.
d. C e n trifu g e fo r 1 m in u te a t m a x im u m sp eed to rem o v e th e re s id u a l
alcohol.
6. E lu te th e plxage g e n o m ic DNA fro m e a c h eolu m n :
o

D o o o f a ll o w th e T E t o c o o l b e lo w 8 0 'C b e f o r e It ia a p p lie d t o t h e c o lu m n .

a. T ra n s fe r Lhc co lu m n to a clea n , au to c la v ed , p ro p e rly lab eled m icro ccn trifu g c Lube.
b. R ap id ly ap p ly 5QgL o f p rc-w arm ed , 8 0 “C TE to th e re s in in th e o olunm .
L et th e TE sit o n Lhc o o lu n m 3 0 to 6 0 se c o n d s to d isso v lc Lhc DNA.
c. C e n trifu g e fo r 1 m in u te to e lu te y o u r p u rifie d p h a g e g e n o m ic DNA.
7. C o m b in e th e DNA sam p le s in to a sin g le tu b e.
8. S to re y o u r DNA a t 4 'C u n til y o u a r e re a d y to q u a n tify a n d an a ly z e it.
G.

D eterm in e th e c o n c e n tr a tio n o f you r DNA.
U sin g a s p e c tro p h o to m e te r (flu o ro m eter, o r N a n o d ro p ) a n d a p ro to c o l from
y o u r in s tru c to r, q u a n tify y o u r DNA.

Q u e stio n s
1. D rew , w h o Is in cred ib ly c o n s c ie n tio u s a n d c a r e s d e e p ly a b o u t th e en v ir o n m e n t,
d e c i d e d it w o u ld b e b e s t t o u s e th e s e m e p a ir o f g lo v e s t h r o u g h o u t to d a y 's
p r o c e d u r e . W hy i s th is , a lth o u g h g o o d fo r t h e e n v ir o n m e n t. ■ p r e tty b ed id e a
fo r to d a y 's p r o c e d u r e ?
2 . A n a q u e o u s a lc o h o l s o lu t io n ia u s e d t o “ w a s h " t h e s a lt s fr o m t h e c o lu m n .
W hy n o t ju st u s e s t r a ig h t a lc o h o l?

t 'a r t 1 D i s s e c t B 3
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Procedural N o tes
M ake th e 80% isop rop an ol u sin g a fresh bottle of reagen t-grade isop rop an ol that h a s b e e n sto red at
room tem p eratu re. A s a lc o h o ls a b so rb w ater from th e air, their con centration ch a n g es.T h e p h a g e
g e n o m ic DMA sticks to th e resin u nd er con d itio n s o f high sa lt or high a lcohol. The DNA will c o m e off
th e co lu m n m s o lu tio n s that lack sa lt or a lcohol.T his m ea n s that if th e isop rop an ol is n ot actually 80%,
th e DNA will b e w a sh ed o ff th e co lu m n at th is ste p a n d th row n aw ay.
2.
ft Is a g o o d id ea to read th e Plromega Kit in s e r t You will n o te that the binding cap acity o f each co lu m n
is 1 2 -l^ r g o f DNA under ideal co n d itio n s. O verloading th e colum n can b e a s bad or w o rse than
under-loading, in term s o f DNA yield.

3.
S tu d e n ts m u st u s e their fitter-sterilized p h a g e ly sa tes for th is s te p , any other sa m p le will d o g th e
co lu m n , tf th ere is d ou b t th a t th e sa m p le w a s f ilter-sterilized b efo re sto r a g e or if particulate m atter is
ap paren t, rep eat th e fiiter-stenlization step . If lysate c lo g s th e sterile filter, centrifu ge th e ly sa te for 20
m in u tes at IQ.OOOxg, d eca n t th e su p em a ta n t into a clean 50-mL screw -ca p tu b e , and retilter.

P*n i iM m m l R-Fa
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Appendix H: Kevin Leslie PCR Protocol
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PCR Checklist

Title:

□

Date:

Step 1
Calculate th e total number of sam ples. The total number of sam ples is the number of
sam ples run, plus a w ater control, plus one extra to hedge against pipetting errors. In
addition, diagram the proper thermal cycler program corresponding to your primers. If
th e program is saved already, identify the thermal cycler and program name.

Master Mix

1 Samnle

3OX Buffer
UlmKu.ul\z:->mM
eachicidi.vidu.tl dVT'’| UN 1i

# Total Samples

Total Volume

Sul

X

~

4ul

X

=

MgCI2

4ul

X

~

niuv

Fwd Pnmer:

2ul

X

=

ujuM

Rev Primer:

2ul

X

=

Taq Polymerase

.25u!

X

—

3unuwui

U ser Name:

Thermal Cycler: New / Old
j
j

Optional
Hot Start

|

Program Name:

Cycles

'

,

Cycle (s)

i
i

i
\
Y /N

f
i

'

'

—

/

ii

\

I

Temp(°C}

u .p r

(
[

1

Tim e

05:00

!

------ ‘ ------

i

-------

When finished with PCR reaction, cut
out and secure in lab notebook
ch eck list c o n tin u e s on back
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^

□
□
□
□
□
□
□
□

□

Step 2
Obtain ice bucket and fill with ice from prep room down the hall
Step 3
G ather a ppropriate mix com ponents, ensuring positive identification of forw ard and reverse primers.
(Thaw briefly in w a ter bath if necessary). Place all com ponents in ice bucket w hen thaw ed
Step 4
O btain a small, sterile epi tu b e. Label th e tu b e "M aster Mix". Into this tu b e, add calculated am ount of
each com ponent from Step 1. Change th e pipette tip after each com ponent addition. W hen finished,
place "M aster Mix" tu b e in ice bucket and return all original com ponents to original locations in
freezers/fridges
S tep S
O btain and label a p propriate num ber of sterile PCR tu b es to ensure each sam ple can be properly
identified
Step 6
O btain DNA sam ples for each of th e chosen strains and thaw them on ice, or, VERY briefly in a w ater bath.
Place in ice bucket for use in upcom ing steps
Step 7
Add 17.25ul of "M aster Mix" to each PCR tube. Changing the tip is not necessary during this step (because
th e tu b es are em pty), but can be done if preferred
Step 8
Add 31.75ul of sterile, distilled w a ter to each of th e PCR tubes. Change th e tip after each addition
Step 9
Add l.OOul of appropriate tem p late DNA (gDNA 100-200ng, plasmid DNA ~50ng) to each PCR tube.
Change the tip a fte r each addition
Step 10
Flick each tu b e several tim es (or vortex briefly) to mix com ponents to g e th e r
Step 11

□

Return all DNA sam ples to original locations in freezers/fridges

□
□

Step 12

□

Centrifuge PCR tu b es for 10-15 seconds in m icrocentrifuge using "Quick" button. (Ensure tubes are
balanced (insert w a ter tu b e if necessary))
Step 13
Ensure all caps are closed tightly. Place tu b es in appropriate therm al cycler, placing them tow ards th e
c e n te r of the manifold and avoiding th e edges (uneven heating). Ensure lid is sealed (two clicks heard
a fte r screwing down top)
Step 14
Run appropriate program on therm al cycler
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Appendix I: In Vitro Methvlation Protocol
Reagents
Extraction buffer (also keep reagents on hand separately):
-20mM Tris-acetate (pH 7.9)
-50mM Potassium acetate
-5mM Na2EDTA
-Im M dithiothreitol (DTT)
-Protease Inhibitor Cocktail (Complete, Mini; Boehringer Mannheim OR Sigma)
SAM (Sigma)
Plasmid DNA (minimum of 12ug)
H. pylori strain to be transformed (log growth phase, OD600 = 0.6-0.9)
lOmM Tris-HCl (ph 7.5)
Filter sterilized SFBB broth
SFBB/Kanamycin Plates
Equipment:
Spectrophotometer
Centrifuge
High-speed centrifuge
Sonicator
Procedure
Bacterial extract preparation
-Harvest log-phase H. pylori cells from one blood agar plate and suspend in 5mL of filter sterilized
SFBB in a 15mF falcon tube
-Take an OD600 reading using the spectrophotometer. Confirm that OD600 value is between 0.6 - 0.9
-Centrifuge original cell suspension in falcon tube at 1800 x g for 10 minutes
-Resuspend cell pellet in 5mF of extraction buffer
-Sonicate cell suspension (on ice)
-Centrifuge sonicated suspension at 15,000 x g for 5 minutes at 4 degrees C
-Remove supernatant and freeze at -80 degrees C (or use immediately)
-Determine concentration of protein extract using A280 Nanodrop reading
Treatment of plasmid DNA with H. pylori strain protein extract
-Combine 12ug of plasmid DNA with 300-400ug of H. pylori protein extract in a 50uF tube containing
{20mM Tris-acetate (ph 7.9), 50mM potassium acetate, 5mM Na2EDTA, ImM DTT and 200 uM
SAM}
-Incubate in water bath at 37 degrees C for 1 hour
-Extract plasmid DNA using phenol-chloroform procedure (see “Forsyth Fab Protocols” binder)
Transformation of H. pylori with treated plasmid
-Conduct transformation as per protocol in “Forsyth Fab Protocols” binder, using treated plasmid
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Appendix .T: Mitomycin C Induction Protocol

Protocol for Induction of One Helicobacter Pylori Strain
Dr. Mark Forsyth’s Laboratory (March 2009)
Protocol by Mark Forsyth and Kevin Leslie

v

'° b

(Approximate Time Required: 7.5 days)
1-Incubate desired strain on a single blood agar plate until growth is sufficient for passing to two separate
BAP’s (Blood Agar Plate, henceforth abbreviated as such). After both plates have grown to “passing”
levels, follow the protocol below:
2-Combine 27mL o f SFBB/lOmM M gS04, 3mL FBS or NCS, and 30pL Vancomycin in a 50mL Flacon
tube. Label tube “Broth Stock.” (If more than 30mL of broth is necessary', use the same proportions of j
ingredients (90% SFBB/1 OmM MgS04, 10% NCS or FBS, 0.1% Vancomycin))
/
3-Using a single sterile swab, pass the bacteria from all three plates into a single 15mL Falcon tube
containing 5mL o f the aforementioned “Broth Stock.” Label the tube “(Strain) Suspension”.
4-Determine concentration of newly created cell suspension via spectrometry (OD600) using dilutions:
-Pipette 500 pL of pure broth stock into empty spec, sample tube (BLANK)
-Pipette 450 pL of broth and 50 pL of cell suspension into empty spec, sample tube (1:10)
-Pipette 495 pL o f broth and 5 pL of cell suspension into empty spec, sample tube (1:100)
(Take two readings for each of the two non-blank samples)
5-Calculate and record the average non-diluted suspension concentration value

+

,f*

6-Divide the remaining volume of “(Strain) Suspension” into three equal volumes amongst three 16mm
Glass (metal capped) tubes. Add “Broth Stock” to achieve a total volume (broth + suspension) of 7mL in
each tube. Using the previously determined concentration value, calculate and record the concentration
for the new samples. Label the tubes “(Strain) M l”, “ (Strain) M2”, and “(Strain) Control” respectively.
7-Place all three tubes in the rotating rack located in the upper incubator. Set a timer for 6 hours and
rotation speed at approximately 60%. Ensure that C02 levels are normalized (between 50-100 on the
gauge).
8- After 6 hours o f incubation, pipette 7 pL o f MitomycinC into each of the two “M” labeled tubes. Add
nothing to the control tube.
9-Place all three tubes back in the rotating incubator and check C02 levels.
10-Incubate all three tubes overnight (approximately 18 hours) at 60% rotation speed
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11-After overnight incubation, transfer all three samples into their own labeled 15mL Falcon tubes.

12-Immediately place the sample “M l” (in its respective falcon tube) into a -80 degrees Celsius freezer.
Placement in a standard tube rack within the freezer is preferred
13-Centrifuge the remaining two tubes (M2 and Control) using Program #1 for 10 minutes. Ensure that
the proper 15mL Falcon tube rotator is inserted and secured in the machine. Additionally, ensure that the
rotator is properly balanced (add additional water tubes if necessary).
14-After centrifugation, remove the supernatant from both tubes and discard.
15-Pipette 7mL of fresh “Broth Stock” back into each of the two tubes
16-Resuspend the cell pellets in the newr media via vortexing
17-After suspension of both of the pellets has been achieved, pipette the samples back into sterile,
respective glass 16mm tubes with metal caps.
18- Place the tubes back in the rotating incubator overnight, using a rotation speed of 60%. Ensure that
C02 levels are normalized.
19- After overnight incubation, pipette the samples into respective, labeled 15mL tubes and immediately
place them in the -80 degree Celsius freezer, preferably in a rack.
20-Thaw within no more than seven days and proceed with slide creation protocol from Dr. Williamson
(shown below)
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Appendix K: Big Dye Sequencing and DTR Gel Cartridge Filtration Protocols

Fluorescent Seanenciny Reactions using Big Dve
- Plasmid mini-preps for sequencing are optimally prepared using Qiagen Spin Plasmid
Mini-prep Kit, although Promega Wizard preps work also.
- PCR amplicons need to be purified via Qiagen PCR Purification Spin columns OR gel
purified. Amplicons can be quantified with reasonable accuracy by comparing the
intensity of the Ethidium Bromide stained band with those band of the 100 bp ladder or
1 kB ladder from New England Biolabs.
Sequencing reactions (prepared on ice at all times!)
X pi DNA to be sequenced (1 pg plasmid OR 150 ng purified PCR amplicon)
1 pi of 15 pM sequencing primer (see tables from PE catalog for conversion from pg to

4

X ul sdH,0 (to bring volume to 18 pi)

^ ^

2 Ml Big Dye Terminator Reaction Mix (Add last)

^

a

mix gently and pulse down quickly.

Cvcle Sequencing Program

u

V y}
-r-K ^

\

3 A^. dt f-f O

^

e

«

\r~ r

yLjA

Hot start 94°C, 5 min.

ia
H y4

THEN;
26 cycles of: 94° C/45 sec, 50X730 sec, 60°C/4 min.
THEN; 4°C hold

^

e
^7 'iA /
W X jU rtP
^ t Q fJ

Purification p/ S^ u e n c m g j^ c tio ns

Use DTF Gel Filtration Cartridges (Edge BioSystems) according to manufacturer’s

pay special attention to the g
force used in the pfuge! (also the time).
protocol, ( d t f cartridges stored at 4°c) -
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■>

Big Dye Sequencing Reaction Purification and Vacuum Drying Protocol

1. Use DTR gel filtration cartridges from the refrigerator, place in centrifuge for 2
minutes at 3000 RPM.
2.

Remove the filter and place it in the special eppendorf tubes provided.

3.

Transfer the sequencing rxn product into the DTR filter/eppendorf tube(place the
solution close to the filter, making sure it doesn’t cling to the sides of the tube).
Be sure to use a new pipet tip for each sample.

4. Centrifuge for 2 minutes at 3000RPM.
5.

Discard the filter, keep the contents of the eppendorf tube.

6.

Place in the vacuum dryer (found in the basement) with the lids of the tubesopen.
Set the dryer to medium, and dry for 45-50 minutes. Flick the tube at the base to
confirm that all fluid was removed. If the sample is still wet, dry for an additional
10-15 minutes and flick again. Repeat if necessary.
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Appendix L: Natural Transformation of H. pylori

“Natural” transformation H pylori bacteria
1. inoculate 4 plates of blood agar plates with a wild-type h. pylori.
2. Grow 24 hours at 37 C and 5% C 02.
3. Remove growth with a sterile cotton-tip applicator, one per plate, and rinse cells off into a
microfuge tube containing 1 ml Brucella broth, squeezing applicator cotton up against side
of tube to salvage as much broth as possible.
4. Spin down in microfuge for 2’ at 6000 rpm.
5. Remove supernatant.
6. Bring back up in 100 p,L Brucella broth/20 ug vancomycin/ml.
6a-add DNA to be transformed to this 100 ul (best to have heat treated the DNA to sanitize
- -8 0 degrees C /20 min) and mix.
7. Spot 30 uL onto the center of a blood agar plate. Repeat with other plates.
8. Place plates, face up, into incubator and grow at 37 C and 5% C 0 2 for about 4 hours.
10. With a cotton-tip applicator, spread cells over agar plate and grow overnight.
11. The next day, harvest cells with a cotton-tip applicator and culture onto entire face of BB
plates with appropriate antibiotic.
12. Grow for 3-5 days, checking colonies each day. Discreet colonies will appear.
13. Pick up to 10 colonies with a toothpick and culture onto blood agar plate a patch about
the size of a quarter. Grow 1-2 days.
14. With a cotton-tip applicator, spread patch of cells onto an entire blood agar plate. Grow
24 hours. From this blood agar plate, culture a BB/antibiotic plate and another blood agar
plate.
15. Harvest cells. From the blood agar plate, extract chromosomal DNA. From the BB
plate, harv est cells and use for freezer stock.
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Appendix M: Transformation of E. coli JM109 Cells
1- Combine 50uL of JM109 competent E. coli cells and 5uL of ligation reaction in a 1.5 mL tube.
2- Place tube on ice for 45 minutes
3- Place tube in 42 degree Celsius heat block for 70 seconds
4- Place tube on ice for 2 minutes
5- Add 500 ul of S.O.C. media to tube
6- Incubate tube for 60 minutes in 37 degree Celsius rotating non-C02 incubator
7- During 60 minute incubation prepare plates as follows:
-Pipette 40 ul of 40mg X-GAL on to the center o f each of three LB-Ampicillin agar plates.
-Spread X-GAL with sterile beads
-Leave plates to set at room temperature for 30 minutes (leave beads on plates)
8- After the 60 minute incubation is complete, onto each of the three LB-Ampicillin/X-GAL agar
plates, pipette 50 ul, 100 ul, and 350 ul, respectively, of transformation reaction. Spread the liquid
across the surface of the plates using existing beads.
9- Discard beads
10- Place all three plates in a 37 degree non-C02 incubator for no more than 24 hours
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Appendix N: Dual-Digest Protocol (adapted from NE Biolabs recommendations)
1- Combine the following in a microcentrifuge tube
lOul (~100ng/ul) DNA sample to be digested
3ul lOx Buffer (specific to restriction enzyme being used)(refer to NE Biolabs catalog)
1.5 ul Restriction Enzyme #1
1.5 ul Restriction Enzyme #2
14 ul Sterile, Distilled Water
TOTAL VOLUME: 30 ul
2-Vortex tube and centrifuge briefly
3-Incubate in a heat block for 2 hours at 37 degrees Celsius
4-After two hours incubation, store at -20 degrees Celsius or proceed with purification protocols
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